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Jaime Marie Brozowski: G protein-coupled receptor kinase 3 (GRK3) regulates G protein-
coupled receptors on murine bone marrow niche mesenchymal stem cells and hematopoietic 
stem-progenitor cells 
(Under the direction of Teresa K. Tarrant) 
The bone marrow microenvironment, termed niche, supports hematopoietic cell 
development and thus, is vital for establishment of the immune system. Within the niche 
reside bone marrow mesenchymal stem cells (BmMSCs) that surround the hematopoietic 
stem-progenitor cells (HSPCs) to support their development, maintenance, and function; 
however, the intracellular regulatory mechanisms of BmMSCs and HSPCs are still being 
defined. The goal of this dissertation work is to provide further insight into the regulatory 
mechanisms that modulate functionality of BmMSCs and HSPCs. Our data suggest G 
protein-coupled receptor kinase 3 (GRK3) functions as a negative regulator of G protein-
coupled receptors (GPCRs) on BmMSCs and HSPCs. 
BmMSCs isolated from GRK3-deficient (Grk3-/-) mice have enhanced proliferation 
and osteogenic differentiation ex vivo compared to wildtype (WT) BmMSCs. Grk3-/- 
BmMSC cultures also have higher levels of CXCL12, an essential chemokine for HSPC 
development, and interestingly, Grk3-/- mice have increased hematopoietic cell numbers 
isolated from the bone marrow. Both Grk3-/- BmMSC proliferation and osteogenic 
differentiation were reduced to WT level upon reduction of sphingosine-1-phosphate (S1P), 
and Grk3-/- BmMSCs have sustained ERK1/2 signaling upon stimulation of sphingosine-1- 
phosphate receptor (S1PR) with S1P in comparison to WT BmMSCs. In addition, we report 
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GRK3 recruits β-arrestin, a protein necessary for receptor internalization, to the C-terminus 
of S1PR1, and we demonstrate BmMSCs lacking GRK3 regulation have impaired S1PR1 
internalization. Our findings suggest GRK3 regulates GPCR S1PR on BmMSCs. 
Grk3-/- mice have increased bone marrow lineage negative (Lin-) Sca1+ c-Kit+ (LSK) 
HSPC and oligopotent progenitor numbers, as well as increased total leukocytes in the 
peripheral blood. Since increased stem cell numbers and function potentiate cellular 
engraftment and hematopoiesis, we tested whether GRK3 deficiency enhances hematopoietic 
cell function in vivo after short-term transplantation, termed colony forming unit-spleen 
(CFU-S) assay. Transplanted Grk3-/- LSK HSPCs or Grk3-/- whole bone marrow increases 
colony counts on the explanted spleen in comparison to WT controls, suggesting 
hematopoiesis of Grk3-/- HSPC is enhanced. Further, both Grk3-/- hematopoietic myeloid 
granulocytic and monocytic (CFU-GM) and lymphoid (CFU-Pre-B) colony counts increased 
ex vivo upon CXCR4 ligand stimulation (CXCL12), and Grk3-/- myeloid colony counts 
reduced to WT levels with CXCR4 antagonist treatment (AMD3100). Taken together, in vivo 
and ex vivo CFU data suggest GRK3 regulates bone marrow HSPC numbers, and this is, at 
least in part, mediated through CXCL12/CXCR4 stimulation. 
Herein, we describe a newly elucidated pathway of regulation on two niche cells, 
BmMSCs and HSPCs. Specifically, our data suggest GRK3 functions as a negative regulator 
of GPCRs on both BmMSCs and HSPCs and can modulate stem cell function. 
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CHAPTER 1: INTRODUCTION— THE BONE MARROW NICHE1 
 
Overview 
 The bone marrow microenvironment, termed niche, is an active area of ongoing 
research, since the niche is critical in maintaining and directing hematopoietic stem cells 
(HSCs)—the most primitive cells that undergo self-renewal activity and differentiate into all 
the hematopoietic lineages that comprise the immune system. Mesenchymal stem cells, 
osteoblasts, and CXCL12-abundant reticular (CAR) cells are key cellular components of the 
bone marrow niche that surround HSCs and direct cell development and functionality, which 
is mediated, at least in part, through G protein-coupled receptors (GPCRs). Here, we discuss 
such complexity of the bone marrow, including historical and modern-day revelations, 
different regions of the bone marrow and key niche cells, mechanistic GPCR interactions 
within the niche, and targeting such GPCRs for therapeutic applications. 
 
Healing Properties of Hematopoietic Cell Transplantation 
 In the 1950s, Dr. E. Donnall Thomas discovered infusion of human bone marrow 
cells could establish new blood cells and repopulate the bone marrow. In 1959, Dr. Thomas 
performed the first successful hematopoietic cell transplantation (HCT) among monozygotic 
twins to treat one twin that was diagnosed with leukemia [1]. In 1968, Dr. Robert Good and 
                                                             
1Adapted from my first-author review article: Brozowski JM, Billard MJ, Tarrant TK. Targeting the Molecular 
and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease. Curr Allergy Asthma Rep. 2014 
February; 14(2):402, of which JM Brozowski researched the review article topics, compiled the resources, wrote 
the journal article, and made all the figures/tables. For this dissertation, JM Brozowski also made Figure 1.1. 
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colleagues performed the first successful HCT among individuals whom were not identical 
twins to treat one sibling diagnosed with an immune deficiency [2]. Further, in 1969, Dr. 
Thomas and colleagues performed the first HCT using a HLA-matched sibling donor [1]. 
Due to these historical revelations, HCT has become the standard of care to treat several 
forms of malignant and non-malignant diseases in modern-day [3]. 
 
Historical Relevance of the Bone Marrow Niche 
While physicians were discovering the healing properties of the bone marrow during 
HCT in the 1950s-1960s, research scientists were beginning to understand the cellular 
rationale and importance of the bone marrow. Research scientists Till and McCulloch first 
observed proliferative bone marrow cells in vivo in the early 1960s [4]. After irradiation and 
injection of donor bone marrow cells, nodules were visualized on a mouse spleen, and 
nodules were comprised of cells that visually resembled hematopoietic cells upon 
microscopy evaluation. Till and McCulloch proposed each nodule stems from one self-
renewing cell, which was experimentally tested in 1963 and established the foundation for 
the current colony forming unit-spleen (CFU-S) assay [5]. Today, we understand that due to 
murine extramedullary hematopoiesis in the spleen, transplanted bone marrow cells with self-
renewal capabilities home to the spleen and form clonal nodules, termed colonies, which can 
be easily visible and enumerated by eye [6]. This CFU-S assay is commonly used today as a 
short-term transplantation assay to evaluate in vivo HSC function. Furthermore, in 1968, 
Friedenstein observed that a single bone marrow cell was capable of forming fibroblastic–
like cells, which uncovered the identification of bone marrow stromal cells [7]. The research 
of Till, McCulloch, and Friedenstein through the 1960s and 1970s demonstrated the bone 
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marrow is comprised of a heterogenous population composed of hematopoietic [4, 5, 8, 9] 
and stromal cells [7, 10-15], and later in 1978, Schofield proposed the concept of a niche, 
where these cells associate with one another to elicit cellular behaviors [16, 17]. Thus, in 
1978 the bone marrow niche was born. 
 
Cellular Components of the Bone Marrow Niche 
Hematopoietic stem cells. 
 The hematopoietic cells Till and McCulloch identified in vivo that had created a 
clonal nodule were, in fact, hematopoietic stem cells (HSCs). HSCs are the most primitive 
cells within the bone marrow that have the abilities to duplicate themselves over and over, 
termed self-renewing, and differentiate into several (hematopoietic) lineages that constitute 
the immune system, termed multipotent.  
Murine hematopoietic stem-progenitor cells (HSPCs) include all multipotent 
hematopoietic cells, identified by having a lack of markers indicative of specific lineage 
commitment, termed lineage marker negative (Lin-), and two positive markers: Sca1 and c-
Kit (CD117), termed LSK HSPCs. Within the LSK HSPC population reside the most 
primitive murine HSCs—long-term HSCs (LT-HSCs) identified as LSK Slamf1(CD150)+ 
and Slamf2 (CD48)- [18-20] and short-term HSCs (ST-HSCs) identified as LSK 
Slamf1(CD150)- and CD48- [18, 21]. ST-HSCs possess less self-renewal capabilities in 
comparison to LT-HSCs. 
Importantly, these multipotent HSCs differentiate into progenitors with more limited 
differentiation potential, termed oligopotent progenitors. The mature myeloid and erythroid 
lineage blood cells differentiate through an oligopotent progenitor, termed common myeloid 
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progenitor (CMP), which terminally differentiates into neutrophils, monocytes, basophils, 
eosinophils, erythrocytes and megakaryocytes/thrombocytes. Alternatively, multipotent 
HSCs can also differentiate into the lymphoid lineage blood cells through an oligopotent 
progenitor, termed common lymphoid progenitor (CLP), which terminally differentiates into 
T lymphocytes, B lymphocytes, and natural killer cells [22]. 
Interestingly, while the self-renewing, multipotent HSCs are most commonly located 
within the bone marrow, they may also mobilize into the peripheral blood upon stress 
responses, such as during inflammation or bleeding [23, 24], or upon regimen-treatments 
used to mobilize stem cells as a source for transplantation. Thus, the self-renewal activity 
(proliferation), multipotency (differentiation), and mobilization (migration/homing) are key 
functions of HSCs, which will be discussed in Chapter 3.  
 
Mesenchymal stem cells. 
 Bone marrow-derived MSCs (BmMSCs) are stromal cells that originate within the 
bone marrow and possess self-renewing and multipotent characteristics, similar to HSCs, 
though differentiate into mesodermal lineages, such as osteocytes (bone), chondrocytes 
(cartilage), and adipocytes (fat) [25]. BmMSCs are a heterogenous population that must 
adhere to three criteria to be deemed a true stromal mesenchymal stem cell, (1) adhere to 
plastic during culture (with stromal-like morphology), (2) possess multipotency, and (3) 
express certain surface marker proteins [26]. While the International Society for Cellular 
Therapy (ISCT) has strict definitions for human BmMSCs marker proteins, those for murine 




BmMSCs are a key component of the bone marrow niche, as they secrete soluble 
factors that are essential for HSPC development and function, such as chemokine CXCL12 
(ligand for CXCR4) [31-33]. Depletion of either CXCL12 or total numbers of BmMSCs 
decrease the HSC pool and repopulating activity, as well as affect homing abilities of HSPCs 
after transplantation [32-34], suggesting BmMSCs impact hematopoiesis. However, further 
characterization of these BmMSCs is warranted to aid a better understanding of their 
biological activity, role within the bone marrow, and therapeutic potential. As such, the work 
within this dissertation further characterizes the regulation and functionality of BmMSCs 
through GPCR signaling, which will be discussed in Chapter 2.  
 
Osteoblasts. 
 Osteoblasts are located within the bone marrow alongside of the endosteum and 
medullary cavity interface and form bone mediated through synthesis, deposition and 
mineralization of extracellular matrix. Earlier studies demonstrated osteoblasts support in 
vitro HSC expansion and secrete factors, including CXCL12 similar to BmMSCs, to regulate 
HSC function [35, 36]. Further studies have shown an increase in osteoblast numbers 
enhances the number of HSPCs in vivo [37, 38], and conditional ablation of osteoblasts 
reduced bone marrow cellularity and thus, the number of HSCs [39], suggesting osteoblasts 
are key cells within the bone marrow affecting HSPC activity; however, direct interactions 
between HSCs and osteoblasts are an ongoing area of scientific investigations. More recent 
findings now suggest osteoblasts may play a more prominent role in supporting lymphoid 




CXCL12-abundant reticular (CAR) cells. 
 The Nagasawa laboratory identified a distinct population of reticular-like cells with 
long cellular processes that highly secrete chemokine CXCL12 and were equally distributed 
throughout the bone marrow. These newly identified reticular cells were termed, CXCL12-
abundant reticular (CAR) cells, and are located surrounding sinusoidal endothelial cells or 
near the endosteum [40]. CAR cells have positive cell marker expression of VCAM-1, CD44, 
PDGFRα/β and are negative for Sca1, CD45, or CD31 cell marker expression [41]. 
 HSCs are found in contact with CAR cells; thus, disruption of the CAR cells impacts 
the bone marrow niche with decreased size and number of HSCs with specific reduction in 
lymphoid and erythroid progenitors, as well as reduced secretion of both CXCL12 and stem 
cell factor and adipogenic and osteogenic differentiation potential of marrow cells. Depletion 
of CAR cells, however, did not affect osteoblasts or endothelial cells [42]. Thus, CAR cells 
are believed to be required for the development and maintenance of HSCs and 
lymphoid/erythroid progenitors [41, 42]. 
 
In summary, BmMSCs, osteoblasts, and CAR cells are all key inhabitants of the bone 
marrow niche that aid hematopoietic cell development and function. As previously described, 
BmMSCs, osteoblasts, and CAR cells each secrete a key bone marrow niche chemokine, 
CXCL12. However, conditional-knockout of CXCL12 in each of these cells contributes to a 
very specific bone marrow phenotype. Depletion of CXCL12 from BmMSCs reduces HSCs, 
long-term repopulating activity, quiescence, and CLPs; however, depletion of CXCL12 from 
CAR cells and osteoblasts did not affect HSCs, but reduces lymphoid progenitors. 
Interestingly, depletion of CXCL12 from mineralizing osteoblasts did not affect HSCs or 
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lymphoid progenitors [32, 33]. Therefore, such data suggest BmMSCs, osteoblasts, and CAR 
cells and the soluble factor CXCL12 participate in an intricate complexity within the bone 
marrow niche during immune cell development.  
 
Regions of the Bone Marrow Niche 
 The bone marrow niche can be described into two functional regions: the endosteal 
niche and the perivascular niche. The endosteal niche is at the endosteum and medullary 
cavity interface with osteoblasts as a key cellular inhabitant, whereas the perivascular niche 
resides along the sinusoidal vessels surrounded by endothelial cells and stromal BmMSCs. It 
has been a long-standing belief that dormant, quiescent HSCs are located near the endosteal 
niche; however, recent studies now suggest HSCs are distributed throughout the bone 
marrow with less than 20% within 10 µm of the endosteum in the endosteal niche and instead 
preferential associate near sinusoid vessels [19, 43-45]. In addition, conditional deletion 
studies showing endosteal niche osteoblast CXCL12 secretions have little to no effect on 
primitive HSCs [32, 33]. Interestingly, after irradiation, HSCs preferentially locate to the 
endosteum, which is believed to be because irradiation causes destruction to the sinusoids 
leaving only arteriolar vessels near the endosteum [45]. Teasing out the niche location and 








G Protein-Coupled Receptor (GPCR) Signaling within the Bone Marrow Niche 
Background on GPCRs. 
 G protein-coupled receptors (GPCRs) comprise 3-5% of the human genome and are 
necessary for several physiological functions. As such, GPCRs serve as therapeutic targets in 
20-50% of marketed pharmaceuticals [46]. GPCRs have seven transmembrane domains with 
an intracellular carboxyl terminus tail, which is essential for receptor regulation. Intracellular 
signaling is induced upon extracellular ligand stimulation, eliciting a conformational change 
and dissociation of guanine nucleotide binding proteins, termed G proteins (α and β/γ) that 
elicit downstream cellular signaling for effector function [47].  
 
GPCR regulation: G protein-coupled receptor kinases (GRKs) and β-arrestin. 
 After ligand-stimulation, G protein-coupled receptor kinases (GRKs) can terminate 
intracellular signaling by phosphorylating the carboxyl terminus of GPCRs, a process termed 
desensitization, which can recruit β-arrestin—protein necessary for GPCR internalization and 
another pathway of GPCR regulation in addition to receptor desensitization [47].  
There are seven GRKs that are classified into three subfamilies: GRK1 (GRK1 and 
7), GRK2 (GRK2 and 3), and GRK4 (GRK4-6); however, GRK1/7 and GRK4 are tissue-
selective with expression in ocular tissues and testes, respectively. Therefore, only GRK2, 
GRK3, GRK5 and GRK6 are ubiquitously expressed [48-52]. While there is sequence 
homology amongst these GRKs, there are clear functional differences with selective 
phosphorylation sites and receptor-specific GRK regulation. Studies utilizing conventional 
murine models of GRK3, GRK5, and GRK6 deficiency have aided our initial understanding 
of the differential role of these GRKs; however, GRK2-deficient mice are embryonically 
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lethal with cardiac hypoplasia, and thus require either heterozygotic or conditional knockout 
models for any research purposes [53]. By utilizing GRK3-deficient (Grk3-/-) mice [54, 55], 
the content of this dissertation reveals a newly identified regulation process by GRK3 on 
sphingosine-1-phosphate (S1P)/S1P receptor (S1PR) signaling to direct the functionality of 
BmMSCs (Chapter 2) and discusses how GRK3 regulation on HSPCs impacts hematopoiesis 
mediated, at least in part, through CXCL12/CXCR4 (Chapter 3). 
 
Ligand-induced GPCR signaling within the bone marrow niche. 
 GPCR signaling in the bone marrow is essential for fundamental processes for 
immune cell development and function [46]. In particular, cellular survival, proliferation, 
differentiation, and trafficking may be hindered if GPCR signaling is impaired. Three 
GPCRs: parathyroid hormone receptor (PTHR), chemokine receptor CXCR4, and S1PR, 
have been described as essential GPCRs in the bone marrow niche and will be discussed. 
 
PTH/PTHR signaling. Parathyroid hormone (PTH) is produced by the parathyroid 
glands and binds PTHR located on bone marrow osteoblasts [56], cells derived from 
mesenchymal stem cells that are responsible for building bone. The Calvi laboratory 
described that mice injected with PTH had increased numbers of HSCs and enhanced 
survival post-transplantation, which is believed to be induced by increased levels of ligand 
Jagged-1 secreted by osteoblasts that binds Notch receptor on HSCs [37, 38]. However, when 
PTH is constitutively activated in terminally differentiated osteoblastic cells, termed 
osteocytes, HSC function and numbers were not altered, suggesting HSC expansion within 
the bone marrow niche mediated through PTH stimulation is cell-specific [57]. Interestingly, 
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despite such promising pre-clinical studies and a phase I study [58], a phase II clinical trial 
that tested whether PTH treatment after transplantation enhanced HSC growth and ability to 
produce new blood cells, termed immune reconstitution, was terminated prematurely due to 
early mortality and lack of efficacy [59]. As previously mentioned, more recent findings now 
suggest osteoblasts may play a more prominent role in supporting lymphoid progenitors 
within the bone marrow niche rather than a direct role with HSCs [32, 33], which may 
partially explain the phase II negative outcome. 
 
CXCL12/CXCR4 signaling. GPCR chemokine receptor CXCR4 binds its cognate 
ligand CXCL12 (stromal cell-derived factor-1, SDF-1) [60], and such CXCL12/CXCR4 
signaling is a key signaling mechanism within the bone marrow niche for steady state 
immune cell development and function. CXCR4 is expressed on HSCs, CMPs, granulocytic-
monocytic progenitors (GMPs), neutrophils, monocytes, and T/B lymphocytes, with low 
expression on myeloid erythroid progenitors (MEPs) [61, 62]. Thus, several leukocyte 
subsets within bone marrow utilize CXCL12/CXCR4 signaling to modulate development and 
function [31]. 
 Interestingly, others have demonstrated GRK3 has selective regulation of CXCR4 
with phosphorylation at serine residues 346/347 (S346/347) [63, 64]. Our lab has further 
demonstrated how GRK3 regulation of CXCL12/CXCR4 signaling is particularly vital for 
mature hematopoietic cell function [55], and the work within this dissertation further 
suggests GRK3 deficiency impacts the function of immature hematopoietic cells, mediated at 
least in part through CXCL12/CXCR4 (Chapter 3). GRK2 [65-67] and GRK6 [68, 69] have 
also been described to regulate CXCR4 in cell lines and mature hematopoietic cells, 
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respectively; however, recent findings suggest the most prevalent GRK in the LSK HSPC 
population is GRK3, and data suggest GRK6 phosphorylation does not play a critical role in 
CXCL12/CXCR4 signaling that is essential during immature hematopoiesis [70]. 
 
S1P/S1PR signaling. The precursor sphingosine is phosphorylated by sphingosine 
kinases (Sphk1 and Sphk2) to produce active ligand S1P that can bind to GPCR S1PRs1-5. 
Most cells contain sphingosine kinase activity in the cytosol and thus, secrete S1P to act in an 
autocrine or paracrine manner [71]. S1P levels are controlled by S1P lyase, which is an 
enzyme that is ubiquitously expressed and irreversibly degrades S1P [72]. S1P has vast 
physiological roles, including serving as a chemoattractant for HSCs. This is achieved with 
lower S1P expression within the bone marrow and high concentrations within the blood, 
thus, creating a chemoattractant gradient for the trafficking of HSCs [73]. S1P also has been 
shown to affect mesenchymal stem cell osteogenic differentiation [74-76] and proliferation 
[77, 78], of which is more clearly defined mechanistically within this dissertation (Chapter 
2). While physiological roles of S1PRs in the bone marrow niche are becoming more 
defined, the regulation of signaling mechanisms are less well understood. Though, Arnon et 
al. elucidated the importance of GRK2 desensitization on S1PR1 to facilitate lymphocyte 
egress from circulation into the tissues [79], and the work described within this dissertation 
suggests the importance of GRK3 regulation on S1PR signaling to modulate BmMSC 
function. Taken together, both studies suggest the importance of S1P/S1PR signaling 





Targeting GPCRs as Therapeutic Strategies in the Bone Marrow 
Hematopoietic cells are retained within the bone marrow by retention signals through 
GPCR signaling. Manipulation of retention signals, such as CXCL12/CXCR4 and S1P/S1PR 
among hematopoietic cells, has been utilized as therapeutic strategies for the treatment of 
various diseases and disorders and will be discussed. 
 
Granulocyte-colony stimulating factor (G-CSF).  
G-CSF has been commonly utilized to enhance egress of HSCs from the bone 
marrow into the peripheral blood [80], for the collection of HSCs to be used in HCT. Data 
have demonstrated G-CSF acts as a HSC mobilizer through disrupting CXCL12/CXCR4 
signaling, as G-CSF treatment induces protease activity in the niche that cleaves both 
CXCL12 and CXCR4 [81]; however, further studies have demonstrated protease-dependent 
and protease-independent mechanisms decrease CXCL12 in the bone marrow [82]. G-CSF 
treatment has also increased S1P levels in the blood [83, 84], which may play a large role in 
facilitating HSC mobilization due to the S1P/S1PR chemotactic gradient.  
 
AMD3100.  
CXCL12/CXCR4 signaling has been discussed as a critical GPCR signaling 
mechanism in the bone marrow niche to aid HSPC development and function. As such, 
CXCL12/CXCR4 serves as a retention signal that is targeted therapeutically by AMD3100, a 
CXCR4 antagonist, to also induce HSC egress from the bone marrow into the peripheral 
blood [85]. Furthermore, combination treatment of G-CSF with AMD3100 enhanced HSC 
egress into the peripheral blood in comparison to G-CSF treatment alone [86].  
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FTY720 and SEW2871.  
FTY720 binds to the S1PR family as an agonist eliciting receptor internalization and 
degradation, thus, suppressing S1P/S1PR signaling due to the reduction of S1PR on the cell 
surface. FTY720 treatment has been shown to suppress the mobilization of HSCs, as well as 
other cells such as T/B lymphocytes [87-90]. Therefore, in contrast to AMD3100, which 
antagonizes CXCL12/CXCR4 signaling and initiates release of hematopoietic cells into the 
periphery, FTY720 suppresses S1P/S1PR signaling through degradation of the receptor and 
inhibits mobilization. As such, FTY720 was FDA approved in 2010 for the treatment of 
relapsing multiple sclerosis by blocking immune cell infiltration into the central nervous 
system [91]. SEW2871 is a S1PR1-specific agonist that recycles the receptor and does not 
undergo degradation. As such, combination therapy of SEW2871 with AMD3100 
substantially enhanced the mobilization of HSCs and progenitors [92].  
 
Conclusion and Research Goals 
The bone marrow microenvironment, termed niche, supports hematopoietic cell 
development and thus, is vital for establishment of the immune system. Within the niche 
reside complex molecular and cellular interactions, evident by the previously discussed 
regions of the bone marrow (endosteal vs. perivascular), key inhabitants (HSCs, BmMSCs, 
osteoblasts, CAR cells), and mechanistic GPCR interactions (PTH/PTHR, CXCL12/CXCR4, 
S1P/S1PR) (Figure 1.1). Novel therapies have been developed by beginning to understand 
the bone marrow niche; however, there is still much to reveal in regards to the intracellular 
signaling and regulation of bone marrow niche cells.  
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Our previous work revealed mice deficient in GRK3 (Grk3-/-), an intracellular 
protein kinase that regulates GPCR signaling, have a hypercellular bone marrow with 
increased LSK HSPCs, oligopotent progenitors, and evident leukocytosis—increased white 
blood cells (termed leukocytes) in the peripheral blood [55]. This observation suggests 
hematopoiesis is enhanced within Grk3-/- mice, though without a clear mechanistic 
understanding. As such, we proposed (1) GRK3 may be directly impacting HSPC GPCR 
Figure 1.1. The bone marrow niche. The bone marrow is categorized into two regions: 
endosteal niche and perivascular niche. Hematopoietic stem cells (HSCs, Lin- Sca1+ c-
Kit+ CD150+ CD48-)/hematopoietic stem-progenitor cells (HSPCs, Lin- Sca1+ c-Kit+), 
bone marrow mesenchymal stem cells (BmMSCs), osteoblasts, and CXCL12-abundant 
reticular (CAR) cells are key inhabitants of the bone marrow niche. GPCR signaling is 
prevalent within the bone marrow niche: CXCL12/CXCR4 and sphingosine-1-phosphate 
(S1P)/S1P receptor (S1PR) signaling is evident on HSC/HSPCs, and the work within 
this dissertation further elucidates the importance of S1P/S1PR signaling on BmMSCs 
(Chapter 2). Parathyroid hormone (PTH)/PTH receptor (PTHR) signaling is evident on 
osteoblasts, cells responsible for bone formation. 
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signaling to elicit an enhanced phenotype and/or (2) GRK3 may be affecting other 
surrounding bone marrow niche cells via GPCR signaling that may be contributing indirectly 
to the enhanced hematopoietic phenotype. 
This dissertation initiates the investigations to address these possibilities by exploring 
regulation of cellular signaling and function of (1) BmMSCs—cells that surround 
hematopoietic cells to support their development, maintenance, and function, and (2) 
HSPCs— cells that are essential for the establishment of hematopoietic lineages of the 
immune system. Specifically, the research goals of this dissertation were to investigate how 
GPCR regulation by GRK3 may impact these two bone marrow niche stem cell populations 
with crucial roles in hematopoiesis. As such, I hypothesized regulation of GPCR signaling by 
GRK3 controls cellular functions of both BmMSCs and HSPCs. 
In chapter 2, my work demonstrates the importance of GRK3 regulation of S1P/S1PR 
signaling in BmMSCs, leading to enhanced BmMSC proliferation and osteogenic 
differentiation when GRK3 regulation is absent. In chapter 3, my work implicates the 
importance of GRK3 regulation of CXCL12/CXCR4 on HSPCs, leading to increased colony 
forming unit (CFU) numbers when GRK3 regulation is absent, evidenced by in vivo short-
term transplantation and ex vivo CFU culture studies. 
Given the important role of BmMSCs within the bone marrow niche, it may be 
possible that such an altered functionality of Grk3-/- BmMSCs revealed herein (Chapter 2) 
has the potential to impact surrounding environments in the bone marrow and affect 
hematopoiesis, though future investigations are warranted and proposed in Chapter 4. In 
addition, since GRK3 deficiency enhances CFU numbers (Chapter 3), and given the positive  
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correlation between the CFU content of a stem cell graft and the success rate of immune 
reconstitution after HCT, it may be possible that GRK3 deficiency could positively impact 
HCT, though future investigations are warranted and proposed in Chapter 4. 
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CHAPTER 2: G PROTEIN-COUPLED RECEPTOR KINASE 3 MODULATES 
MESENCHYMAL STEM CELL PROLIFERATION AND DIFFERENTIATION 
THROUGH SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATION2 
 
Overview  
The bone marrow niche supports hematopoietic cell development through intimate 
contact with multipotent stromal mesenchymal stem cells; however, the intracellular 
signaling, function, and regulation of such supportive niche cells are still being defined. 
Thus, our study was designed to better define the regulation of cellular signaling and 
functional mechanisms of bone marrow-derived mesenchymal stem cells (BmMSCs). Our 
data suggest G protein-coupled receptor kinase 3 (GRK3) functions as a negative regulator of 
G protein-coupled receptor signaling of sphingosine-1-phosphate receptor (S1PR) on 
BmMSCs. BmMSCs isolated from GRK3-deficient (Grk3-/-) mice have enhanced 
proliferation and osteogenic differentiation ex vivo compared to wildtype (WT) BmMSCs in 
identical culture conditions and passages. Grk3-/- BmMSC cultures also have higher levels 
of CXCL12, an essential chemokine for hematopoietic stem and progenitor cell development, 
and Grk3-/- mice have increased hematopoietic cell numbers isolated from the bone marrow.
                                                             
2Brozowski JM, Timoshchenko RG, Serafin DS, Allyn B, Koontz J, Ren Y, Eudy AM, Harris TF, Abraham D, 
Mattox D, Rubin CT, Hilton MJ, Rubin J, Allbritton NL, Billard MJ, Tarrant TK. G protein-coupled receptor 
kinase 3 modulates mesenchymal stem cell proliferation and differentiation through sphingosine-1-phosphate 
receptor regulation. Stem Cells. Submitted September 28, 2017. In revisions for resubmission. 
 
JM Brozowski performed experiments for Figure 2.1, Figure 2.2, Figure 2.4, Figure 2.5, Figure 2.6B, as well as 
appendices 1, 2 (performed replicated run to confirm previous data by RGT), 3, 4, 6, 7, 8 and 13. JM Brozowski 
wrote the journal article, as well as made the figures, including illustration for Figure 2.7. Note: Appendices 3, 
7, 8, and 13 were not originally included within the submitted manuscript on September 28, 2017. 
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However, Grk3-/- mice do not have an enhanced trabecular bone volume fraction, suggesting 
GRK3 deficiency in niche BmMSCs may have more pronounced effects on hematopoiesis as 
opposed to mature bone development in vivo. Both Grk3-/- BmMSC proliferation and 
osteogenic differentiation were reduced to WT level upon reduction of sphingosine-1-
phosphate (S1P), and Grk3-/- BmMSCs have sustained ERK1/2 signaling upon stimulation 
of S1PR with S1P in comparison to WT BmMSCs. In addition, we report GRK3 recruits β-
arrestin, a protein necessary for receptor internalization, to the C-terminus of S1PR1, and we 
demonstrate BmMSCs lacking GRK3 regulation have impaired S1PR1 internalization. Our 
work suggests GRK3 regulates S1PR on BmMSCs, and lack of such regulation affects 
BmMSC functionality. 
 
Significance Statement  
Mesenchymal stem cells are self-renewing cells that have the potential to differentiate 
into multiple different tissue types. This has prompted pre-clinical and clinical investigations 
studying mesenchymal stem cells for the treatment of various diseases; however, rigorous 
studies are ongoing to learn more about tissue-specific signaling, function, and regulation. 
Our work demonstrates the importance of G protein-coupled receptor kinase 3 (GRK3) in 
bone marrow-derived mesenchymal stem cell (BmMSC) signaling and during development 
into pre-osteoblasts through its regulation of sphingosine-1-phosphate receptor. Lack of 
GRK3 receptor regulation enhances BmMSC proliferation and function toward becoming 
osteoblast precursors, which can then impact surrounding environments in the bone marrow 





Mesenchymal stem cells are multipotent stromal cells that possess the ability to 
differentiate into mesodermal tissues, such as chondrocytes, adipocytes, and osteocytes [25]. 
Mesenchymal stem cells that reside within the bone marrow microenvironment, often 
referred to as bone marrow niche mesenchymal stem cells (BmMSCs), secrete high levels of 
chemokine CXCL12 that binds to G protein-coupled receptor (GPCR) CXCR4 on 
hematopoietic stem and progenitor cells (HSPCs) to affect their growth and development [31, 
93]. BmMSCs impact hematopoiesis as depletion of either CXCL12 or total numbers of 
mesenchymal stem cells from the bone marrow decrease the hematopoietic stem cell pool 
and repopulating activity, as well as affect homing abilities of HSPC after transplantation 
[32-34].  
We previously observed mice deficient in G protein-coupled receptor kinase 3 
(GRK3), an intracellular kinase that negatively regulates GPCRs, have (1) a hypercellular 
bone marrow comprised of significantly increased Lin- Sca1+ c-Kit+ (LSK) HSPCs and 
selective downstream committed progenitors, and (2) an increase of total white blood cells in 
the peripheral blood (leukocytosis) compared to WT mice [55]. Our data showed GRK3 
deficiency affects CXCR4 regulation on hematopoietic cells [55]; however, due to the 
importance of stromal cells within the niche that impact HSPC development and function, we 
were also interested in understanding the regulatory role of GRK3 on BmMSCs, in which 
GRK3 is expressed [54]. 
We observed Grk3-/- BmMSCs have enhanced osteogenic differentiation, higher 
levels of CXCL12, and increased proliferation. Accumulating evidence supports that 
phospholipid sphingosine-1-phosphate (S1P) affects mesenchymal stem cell function [46] in 
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osteogenic differentiation [74-76] and proliferation [77, 78]. Since the S1P receptors (S1PRs) 
are GPCRs, our study aimed to elucidate whether GRK3 regulated S1PR on BmMSCs to 
affect their functionality. 
 
Materials and Methods 
Animals.  
Wildtype (WT) C57BL/6 and GRK3-deficient (Grk3-/-) age-matched (8-12 week-
old) mice were used under standard IACUC-approved protocols in the AAALAC-accredited 
vivarium of UNC, and care of animals was in accordance with institutional guidelines. The 
Grk3-/- mouse strain was provided by Dr. Robert J. Lefkowitz (Duke University) and 
backcrossed >12 generations on the C57BL/6 background. 
 
Bone marrow-derived mesenchymal stem cell (BmMSC) isolations.  
BmMSC were isolated from flushed femurs and tibias of two male mice and cultured 
in complete isolation media (CIM) containing RPMI (Corning, 10040CV) with 10% fetal 
bovine serum (FBS, Atlanta Biologicals, S12450), 10% horse serum (HS, HyClone, 
SH30074.03), 1% 100 IU/mL penicillin G/100 µg/mL streptomycin (P/S, Corning, 30-002-
Cl), and 12 µM final concentration of L-Glutamine (Corning, 25-005-Cl), as similar 
methodologies have been previously described [29, 94, 95]. BmMSC expansion was in 
complete expansion media (CEM) containing IMDM (Gibco, 12440-053), 10% FBS, 10% 
HS, 1% P/S, and 12 µM final concentration of L-Glutamine [29, 95], which was followed by 
hematopoietic CD45 (Stem Cell Technologies, 19771) and CD11b (Miltenyi, 130-049-601 or 
130-093-634) depletion, as recommended by [94], via magnetic negative selection at early 
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passages 1-3. BmMSCs were passaged at 70-80% confluency and used for experiments at 
passages 4-15. 
 
Chondrogenic, adipogenic, and osteogenic differentiation.  
Chondrogenic differentiation. BmMSCs were suspended in CEM at 1.6x107 viable 
cells/mL. Micromasses were made by adding 5 µL droplets of the cell suspension onto a 6-
well plate and given 3-4 hours to attach. Chondrogenic media (Gibco StemPro® 
Chondrogenesis Differentiation Kit, A10071-01) supplemented with penicillin streptomycin 
was added to each well and incubated for 21 days. Cells were fixed with 10% formalin and 
stained using Alcian Blue. Adipogenic differentiation. BmMSCs were plated at 1x105 
cells/well of a 6-well plate in CEM supplemented with 50 µM indomethacin, 5 µg/mL 
insulin, and 0.1 µM dexamethasone. Cells were fixed with 10% formalin and stained using 
Oil Red O. Osteogenic differentiation. BmMSCs were plated at 1x105 cells/well of a 6-well 
plate in CEM supplemented with 50 µg/mL ascorbic acid and 20 mM ß-glycerophosphate. 
Cells were fixed with 10% formalin and stained using Alizarin Red. For SKI-treated 
osteogenic differentiation, BmMSCs were plated at 2x104 cells/well in a 24-well plate in 
CEM, and osteogenic differentiation was induced after an overnight rest. Cells were treated 
with sphingosine kinase inhibitor 2 (SKI, Cayman Chemical, 10009222) at a final 
concentration of 5 µM or vehicle (DMSO). Fresh media changes occurred every third day 
using CEM plus SKI or vehicle. Cells were fixed with 10% formalin and stained using 
Alizarin Red stain for analysis. Images were captured using the Olympus 1X-81 microscope 




Bone marker mRNA expression (qRT-PCR).  
Total RNA from BmMSCs undergoing osteogenic differentiation was prepared using 
the RNeasy Mini/ Plus kit (Qiagen) according to manufacturer’s instructions. Reverse 
transcriptase cDNA synthesis was performed using iScript cDNA synthesis kit (Bio-Rad, 
170-8891). qRT-PCR was performed in duplicate (SYBR® Green, Bio-Rad, 172-5271) and 
normalized to housekeeping gene IDUA. Mean fold change of alkaline phosphatase was 
determined by 2-ΔΔCt with WT day 0 as control. Primers utilized for qRT-PCR were Alkaline 
Phosphatase forward: AAG GCT TCT TCT TGC TGG TG, Alkaline Phosphatase reverse: 
GCC TTA CCC TCA TGA TGT CC; IDUA forward: GCA TCC AAG TGG GTG AAG TT 
and IDUA reverse: CAT TGA GCA GGT CCG GAT AC.   
 
ELISA.  
BmMSCs were plated at 1x105 cells/well of a 6-well plate in CEM and rested 
overnight for attachment before supernatant collections began at baseline (day 1) and each 
subsequent collection. Supernatants of undifferentiated BmMSC monolayers were collected 
and analyzed for CXCL12 protein using the CXCL12 DuoSet ELISA kit (R&D Systems, 
DY460), as per instructions. 
 
Micro-computed tomography (µCT). 
For 8-12 week-old mice, µCT imaging was used to analyze the trabecular bone 
morphology at the distal femur at 12 micron resolution. The metaphyseal region of the distal 
femur was scanned beginning 720 microns proximal to the growth plate and extending 1500 
microns towards the diaphysis of the femur. An automatic script was used to analyze the 
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region of interest to separate the trabecular and cortical regions of the bone and quantify bone 
morphology. Trabecular analysis includes quantification of BV/TV (bone volume/total 
volume). For 17-20 month-old aged mice, µCT imaging morphology (VivaCT80, Scanco 
Medical, Basserdorf, Switzerland) was used to analyze the trabecular bone. Briefly, 
metaphysis region was selected for 100 slices under the femur growth plate. Trabecular 
analysis includes quantification of BV/TV. Analyses were conducted at 12 μm slice 
increment with an integration time of 300 ms, a current of 145 mA, and an energy setting of 
55 kV. The threshold was chosen using 2D evaluation of several slices in the transverse 
anatomic plane so that mineralized bone was identified but surrounding soft tissue was 
excluded. 
 
Cellular proliferation.  
Proliferation of 5x104 BmMSCs/well of a 6-well plate was analyzed after exogenous 
CCK-8 (Dojindo Molecular Technologies) was added to each well at the indicated 
timepoints. Absorbance was measured after 3-hour incubation using the Promega Glomax® 
Multi + Detection System. Data were analyzed by deducting background (media and CCK-8) 
absorbance from raw absorbance reads. For S1P studies, BmMSCs were plated at 1x104 
cells/well in a 24-well plate and treated with SKI at a final concentration of 5 µM. 
 
Immunoblotting.  
BmMSCs were plated in CEM at 2.25x105 cell density in a 6-well plate and incubated 
overnight. DPBS rinsed cells were rinsed three times with IMDM containing 20% charcoal-
stripped FBS (to remove serum S1P) and 1% P/S, and incubated at 37ºC for 15 minutes. 
24 
 
Fresh media was added, and BmMSCs were stimulated with 1 µM S1P for indicated 
timepoints. Unstimulated BmMSCs served as 0 minute timepoint control. Following 
stimulation with S1P, BmMSC cells were rinsed with DPBS and lysed in cold HBSS + 1% 
TritonX100 lysis buffer containing protease inhibitors (1 mM PMSF, 1 µg/mL aprotinin, 1 
µg/mL pepstatin, and 1 µg/mL leupeptin) and phosphatase inhibitors (5 mM NaF and 2 mM 
NaVO4). All WT and Grk3-/- BmMSC lysates were normalized via Bicinchoninic acid 
(BCA) assay, and 6 µg of total protein in laemmli sample buffer (non-reducing) was freshly 
loaded onto AnyKD Mini-PROTEAN®TGX precast protein gel (Bio-Rad, 4569036). Gels 
were run at 100V for 1.5 - 2 hours in 1XTris/Glycine SDS buffer. Proteins were transferred 
overnight at 4ºC onto nitrocellulose membrane in Tris base (25 mM)/Glycine (192 mM) 
transfer buffer containing 20% methanol. The membrane was blocked in 3% fatty-acid free 
BSA in TBS plus 0.1% Tween-20 (TBS/T) for 2 hours at 25ºC and incubated with primary 
antibody 1:2,000 phospho-p44/42 MAPK or 1:2,000-3,000 p44/42 MAPK (Cell Signaling 
Technologies, 4370/4695) overnight at 4ºC, or 1:10,000 GAPDH (Trevigen, 2275-PC-100) 
for 2 hours at 4ºC. The membrane was washed three times for 10 minutes in TBS/T, 
incubated with secondary antibody 1:5,000 anti-rabbit IgG HRP (Cell Signaling 
Technologies, 7074) for 1 hour at 25ºC, and washed twice for 10 minutes in TBS/T and once 
in TBS. Detection was performed via ECL Prime or ECL Select (GE Healthcare, RPN2232/ 
RPN2235) and imaged on GeneSys image acquisition software. Densitometry was obtained 






β-arrestin recruitment assay.  
GRK recruitment of β-arrestin to the S1PR1 carboxy-terminus was measured using 
agonist-stimulation in a modified-TANGO assay, as previously reported [96]. HTLA cells 
were transfected with a S1PR1-TCS-tTA receptor construct after removing the V2 
vasopressin sequence to prevent nonspecific β-arrestin recruitment to the wildtype S1PR1. 
GRK over-expression was achieved via plasmids: GRK2 pcMyc_LIC and GRK3 
pcMyc_LIC, and utilized a separate expression vector encoding yellow-fluorescent protein 
(YFP) that was simultaneously transfected to serve as a transfection control. HTLA cells 
were transiently transfected with 6.5 μg of total plasmid DNA (3 μg of S1P-Tango, 0.5 μg of 
YFP, and either 3 μg of empty-vector control, GRK2, or GRK3) via calcium-phosphate 
precipitation. Transfection efficiency was determined by YFP epifluorescence to be 
consistently >70% at 24 hours post-transfection. Cells were serum starved and then 
stimulated with S1P ligand at varied concentrations up to 1 µM. BriteGlo reagent (Promega, 
Madison, WI, USA) was added for luminescence detection via Promega Glomax® Multi + 
Detection System (0.5 sec/ well). Raw data were normalized by subtracting background for 
each independent run and setting the lowest concentration of the control condition at 0% and 
highest concentration at 100%. 
 
S1PR1 internalization assay.  
BmMSCs cultured in CEM were rinsed with DPBS and incubated in serum-free CEM 
(SFM) for 2.5 hours. BmMSCs were detached using Accutase® (Sigma, A6964), rinsed once 
with cold SFM containing 5% charcoal-stripped FBS (to remove serum S1P), and 
resuspended in cold DPBS. 1x105 BmMSCs were stimulated with 1 µM S1P ligand in       
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100 µL FACS buffer (DPBS1X + 0.2% fatty acid free BSA + 0.1% sodium azide) at specific 
timepoints. Unstimulated BmMSCs served as 0 minute timepoint control. S1PR1 
internalization was halted with 2 mL of ice cold FACS buffer and sample tubes were placed 
on ice. BmMSCs were stained for Sca1 (eBioscience clone: D7, APC-conjugated) and 
S1PR1 (R&D Systems clone: 713412, PE-conjugated) for 30 minutes on ice in 100 µL FACS 
buffer, rinsed, and analyzed by flow cytometry. 
 
Statistical analyses.  
All data were graphed utilizing GraphPad Prism v.7 and statistically evaluated using 
GraphPad Prism v.7 or Microsoft Office Excel program. Taking into consideration time and 
strain (WT and Grk3-/-), the bone marker qRT-PCR, CCK-8 proliferation, and S1PR1 
internalization was statistically analyzed using a RM two-way ANOVA with Sidak’s 
multiple comparison test, a method preferred over Bonferroni due to increased power [97, 
98]. Similarly, taking into consideration time and strain (WT and Grk3-/-) but with multiple 
treatment groups, the SKI-treated CCK-8 proliferation was analyzed using a RM two-way 
ANOVA with Tukey’s multiple comparison test for pairwise comparisons [97, 99]. Student’s 
t-test compared two independent groups (WT and Grk3-/-) for the CXCL12-detection 
ELISA, micro-computed tomography data, and western blot densitometry. Taking into 
consideration three independent groups (empty vector, GRK2, and GRK3), the β-arrestin 
recruitment assay was analyzed by one-way ANOVA with Dunnett’s multiple comparison 






Grk3-/- BmMSCs have enhanced osteogenic differentiation.  
In our previous studies, we observed Grk3-/- mice had increased HSPC numbers 
compared to WT mice [55]. Since it is well established that bone marrow stromal cells 
enhance hematopoiesis [32-34, 101-103], we aimed to test whether there were differences 
between Grk3-/- and WT murine stromal BmMSCs that could contribute to this phenotype. 
BmMSCs isolated from WT and Grk3-/- mice adhered to culture plastic, underwent 
differentiation into tissue-specific lineages to ensure multipotency (Figure 2.1A), and lacked 
Figure 2.1. Bone marrow-derived mesenchymal stem cells (BmMSCs) deficient in G 
protein-coupled receptor kinase 3 (Grk3-/-) have enhanced osteogenic differentiation in 
comparison to wildtype (WT) BmMSCs. (A) Multipotent differentiation of BmMSCs 
isolated ex vivo from Grk3-/- and WT mice into chondrocytes (Alcian Blue stain), adipocytes 
(Oil Red O stain), and osteoblasts (Alizarin Red stain) at day 21; images acquired at 10X 
magnification. Differentiation analyses n=3 chondrogenic/adipogenic and n=10 osteogenic. 
(B) Time-course Grk3-/- and WT BmMSC osteogenic differentiation (Alizarin Red stain) at 
2X magnification. Representative images, n=4. (C) Mineralization of bone marker alkaline 
phosphatase expression during osteogenic differentiation relative to housekeeping gene 
IDUA. Data represent mean ± SEM, n=7. 
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expression of CD45 and CD11b (hematopoietic cell markers) and consistently expressed 
mouse mesenchymal stem cell markers Sca1, CD106, CD73, CD44, CD29 (Appendix 1). 
During differentiation analysis, we observed no substantial differences between WT and 
Grk3-/- BmMSC chondrogenic or adipogenic differentiation cultures. However, we observed 
enhanced and earlier osteogenic differentiation in Grk3-/- BmMSC cultures in comparison to 
WT cultures, as demonstrated by positive alizarin red stain (Figure 2.1B) and higher mRNA 
expression levels of alkaline phosphatase (ALP), a marker of osteoblast differentiation that 
peaks near day 14 (Figure 2.1C) [104, 105]. We noticed the enhanced osteogenic 
differentiation phenotype was repeatedly consistent and was reproduced in four separate 
isolations. To further ensure there were no isolation differences between WT and Grk3-/- 
BmMSCs that may induce such a phenotype, we utilized shRNA to knockdown GRK3 
(GRK3-KD) from WT BmMSCs and induced multipotent differentiation, which again 
showed the identical phenotype of enhanced osteogenic differentiation in GRK3-KD 
BmMSCs in comparison to non-target (NT) control BmMSCs (Appendix 2).  
 
Grk3-/- BmMSC cultures have higher levels of CXCL12.  
Niche BmMSCs, CXCL12-abundant reticular (CAR) cells in the bone marrow, and 
pre-osteoblasts secrete CXCL12 [32, 33], an essential chemokine in the niche for HSPC 
development and/or function. Since we observed our Grk3-/- mice had increased HSPCs 
[55], we next tested whether there may be differences in CXCL12 levels between WT and 
Grk3-/- BmMSCs ex vivo. Our data revealed Grk3-/- BmMSC cultures had higher levels of 
CXCL12 detected in comparison to WT BmMSC cultures at baseline, as well as each 




GRK3 deficiency increases proliferation ex vivo.  
Due to the enhanced detection of CXCL12 in Grk3-/- BmMSC culture, we wanted to 
further investigate whether this was the result of enhanced secretory function or a 
proliferation response, since we also observed increased cell counts when passaging Grk3-/- 
BmMSCs. Cell counting kit-8 (CCK-8) quantitates proliferation by absorbance detection of 
increased formazan dye production from viable cells. Using this assay of cellular 
quantification, Grk3-/- BmMSCs have enhanced proliferation over time in comparison to WT 
BmMSCs (Figure 2.2B). 
 
GRK3 deficiency does not affect mature bone formation in vivo.  
As a result of our observed enhancement of Grk3-/- BmMSC osteogenic 
differentiation and proliferation ex vivo, we proposed to investigate whether GRK3 
Figure 2.2. Grk3-/- BmMSCs have higher levels of CXCL12 detected and proliferate 
more in comparison to WT BmMSCs. (A) Quantification of CXCL12 protein 
concentration from supernatant of BmMSC cultures. Lower limit of detection at 46.9 
ρg/mL. Data represent mean ± SEM, n=4. (B) BmMSC proliferation determined by 
increased formazan dye production from viable cells over time using CCK-8 proliferation 
assay. Data represent mean ± SEM, n=3, except day 0 n=2.  
* P<0.05 ** P<0.01 *** P<0.001 **** P<0.0001 
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deficiency affected mature bone development in vivo. Therefore, we performed micro-
computed tomography (µCT) for femoral bone analyses on WT and our conventional 
knockout mouse model of GRK3 deficiency. Despite the propensity of Grk3-/- BmMSCs to 
more readily differentiate into the osteogenic lineage driven by ex vivo reagent stimulation, 
our µCT results did not show differences in the trabecular bone volume fraction of Grk3-/- 
young or aged mice in vivo compared to controls (Figure 2.3A-D).  
Figure 2.3. Femoral trabecular bone density is not differentially affected by GRK3 
deficiency in young or aged mice. Quantification of trabecular bone volume fraction 
(BV/TV) via micro-computed tomography analysis of (A) young and (B) aged Grk3-/- and 
WT mouse femurs. Representative 3D image of trabecular bone of (C) young and (D) aged 
Grk3-/- and WT mouse femurs. Data represent mean ± SEM, n=5 for young mice and n=8 
(WT) n=11 (Grk3-/-) for aged mice. 
31 
 
Inhibition of S1P reduces the enhanced osteogenic differentiation and proliferation 
phenotype of Grk3-/- BmMSCs. 
Since GRK3 regulates GPCRs [54], we next aimed to identify the GPCR that could 
be contributing to the enhanced Grk3-/- BmMSC phenotypes of osteogenic differentiation 
and proliferation. Since we and others have demonstrated that (1) BmMSCs secrete CXCL12 
[32, 33], (2) GRK3 regulates CXCR4 in other cell types [55, 106, 107], and (3) GRK3 
regulation of CXCR4 impact bone marrow hematopoietic cell functionality [55, 108], we 
proposed CXCL12 may be acting via an autocrine CXCL12/CXCR4 signaling loop on 
BmMSCs. However, only low levels of CXCR4 mRNA expression were detected on ex vivo 
murine BmMSCs (Appendix 3) and further functional tests with stimulation or inhibition of 
CXCR4 signaling resulted in no effect on BmMSCs proliferation (Appendix 4).   
Accumulating evidence suggests phospholipid S1P affects mesenchymal stem cell 
function [46], specifically in osteogenic differentiation [74-76] and proliferation [77, 78]. 
Figure 2.4. Osteogenic differentiation and proliferation of Grk3-/- BmMSCs are 
decreased to WT levels with sphingosine kinase inhibitor treatment. (A) BmMSCs 
treated with 5 µM sphingosine kinase inhibitor (SKI) while in osteogenic media for 
differentiation studies and stained with Alizarin Red. Representative images acquired at 
2X magnification, n=3. (B) BmMSCs cultured with 5 µM SKI in culture media for 




Since S1P binds S1P receptors (S1PR), which are also GPCRs, we next hypothesized GRK3 
functioned as a negative regulator of GPCR signaling of S1PR on BmMSCs to affect their 
functionality. To test this hypothesis, we had to address that (1) S1P is readily available in 
the BmMSC culture media due to the naturally high presence in fetal bovine and horse serum 
[109] and that (2) murine BmMSCs secrete S1P [110]. Therefore, to effectively neutralize 
S1P in culture, we utilized a sphingosine kinase inhibitor (SKI), which reduces the 
conversion of sphingosine to active ligand S1P. We also verified that WT and Grk3-/- 
BmMSCs had comparable sphingosine kinase activity before manipulation of this pathway 
(Appendix 5). Titration of SKI to an optimized dose of 5 µM reduced both Grk3-/- 
osteogenic differentiation (Figure 2.4A) and proliferation (Figure 2.4B) to comparable 
levels with WT BmMSCs, suggesting S1PR, and not CXCR4, has a role in the enhanced 
phenotypes.  
 
Grk3-/- BmMSCs have enhanced ERK1/2 signaling after S1P stimulation.  
The ERK signaling pathway has been linked to both mesenchymal stem cell [111] 
and pre-osteoblastic cell line [112] osteogenic differentiation, as well as mesenchymal stem 
cell proliferation [78]; therefore, we hypothesized ERK signaling may be enhanced in Grk3-
/- BmMSCs with S1P stimulation. We show via densitometry ERK1/2 early signaling at 0, 1, 
and 5 minutes is comparable between WT and Grk3-/- BmMSCs (Figure 2.5A, B); however, 
during late signaling, while WT signaling wanes after 30 minutes, Grk3-/- BmMSCs show 




GRK3 recruits β-arrestin to the C-terminus of S1PR1 and affects S1PR1 
internalization. 
While BmMSCs express S1PRs1-3 [113-115], the intracellular signaling, function, 
and regulation of each specific receptor on BmMSCs is still being defined. Recent studies 
have shown stimulatory BmMSC function through ligation of S1PR1 and S1PR3 in contrast 
to inhibition of function after stimulation through S1PR2 [114]. We hypothesized our 
enhanced GRK3-regulatory phenotype may be mediated via S1PR1, since our Grk3-/- 
BmMSCs phenotype showed enhanced proliferation and prolonged ERK1/2 signal activation 
Figure 2.5. Grk3-/- BmMSCs have enhanced ERK1/2 signaling after S1P stimulation 
at later timepoints. (A) WT (left) and Grk3-/- (right) BmMSCs were stimulated with 1 
µM S1P for designated times for analysis of ERK1/2 signaling; phospho-ERK (pERK) 
and total ERK (tERK). Representative blot, n=4. The pERK/tERK ratio for each blot was 
quantified via densitometry for (B) early-stage ERK signaling at 0, 1, and 5 minutes and 
(C) late-stage ERK signaling at 15, 30, and 60 minutes. Data represent mean ± SEM, 
n=4. ** P<0.01 
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analogous to previously reported S1PR1 activation in adipose-derived mesenchymal stem 
cells [78] and S1PR1 was more readily detected on WT and Grk3-/- BmMSCs by protein 
lysate analysis and flow cytometry (Appendix 6), in comparison to S1PR3 that was 
minimally detected (Appendix 7). 
We hypothesized that GRK3 could be involved in S1PR1 β-arrestin recruitment—a 
protein necessary for GPCR internalization and another pathway of GPCR regulation in 
addition to receptor desensitization. Using the modified-TANGO assay [96, 116] with GRK2 
as a positive control [79], we demonstrated GRK3 recruits β-arrestin to the C-terminus of 
S1PR1 (Figure 2.6A). We next hypothesized that receptor internalization was an additional 
means of GRK3/S1PR1 regulation, and thus S1PR1 internalization would be impaired in  
Grk3-/- BmMSCs. In S1P-activated receptor internalization assays, S1PR1 surface receptor 
expression by flow cytometry was prolonged over time in Grk3-/- BmMSCs compared to 
controls (Figure 2.6B), suggesting a defect in β-arrestin-mediated internalization.  
Figure 2.6. GRK3 recruits β-arrestin to the C-terminus of S1PR1 and affects S1PR1 
internalization. (A) HTLA cells transfected with S1PR1-TCS-tTA receptor construct 
and empty vector (negative control), GRK2 (positive control), or GRK3 plasmids and 
stimulated with 1 µM S1P for detection of β-arrestin recruitment response via 
luminescence. Data represent mean ± SEM, n=6. (B) Sphingosine-1-phosphate receptor 
1 (S1PR1) surface expression as measured by median fluorescence intensity compared to 
unstimulated cells (0 min) by flow cytometry. WT and Grk3-/- BmMSCs were 
stimulated with 1 µM S1P at designated timepoints. Data represent mean ± SEM, n=5.  




Mesenchymal stem cells are under active investigation for use in regenerative 
medicine and cell therapy; therefore, there is an essential need for better cellular 
characterization and understanding of their signaling, function, and regulation [117-119]. 
Challenges within the field include ex vivo expansion studies utilizing different tissue-
derived sources of cells, growth media conditions, serum sources and lots, seeding densities, 
and sample variations [117, 120], which can be potential confounders in interpreting data. To 
reduce such confounders, we utilized media previously published to best support BmMSCs 
from C57BL/6 mice [29], maintained the same serum sources and lots throughout all studies, 
seeded and cultured cells at comparable densities, and minimized sample-variation findings 
by design and testing of several different BmMSC isolations from WT and Grk3-/- mice. 
Here, we demonstrate that BmMSCs deficient in Grk3 more readily differentiate into 
osteoblasts upon osteogenic supplementation (Figure 2.1A-C, Appendix 2), produce more 
CXCL12 (Figure 2.2A), and proliferate more ex vivo (Figure 2.2B). We hypothesize that 
these in vitro findings may additionally contribute toward mechanisms underlying the 
enhanced hematopoiesis phenotype that we observed in the Grk3-/- mouse [55]. Previous 
studies have demonstrated depletion of CXCL12 or total numbers of mesenchymal stem cells 
decrease the bone marrow hematopoietic stem cell pool and repopulating activity [32-34]. 
Thus, taken together, we might conclude the enhanced numbers of HSPCs observed in the 
Grk3-/- mouse bone marrow [55] could be partially attributed to the Grk3-/- BmMSC 
enhanced phenotypes described here. However, we recognize that selective Grk3 gene 
targeting of mesenchymal stem cells and/or osteoblasts in vivo would be necessary to 
definitively conclude this, which are the goals of future studies. 
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Here, we demonstrate Grk3-/- BmMSC cultures had higher levels of CXCL12 at 
baseline upon equal seeding densities, and one interpretation is that Grk3-/- BmMSCs have 
an enhanced CXCL12 secretory function, such as has been described of CAR stromal cells in 
the bone marrow [33]. However, our study also detected enhanced proliferation of Grk3-/- 
BmMSCs at later timepoints (Figure 2.2B). This suggests the levels of CXCL12 detection at 
most time points are likely due to increased number of Grk3-/- BmMSCs in culture.  
Despite increased proliferation and enhanced osteoblast differentiation during ex vivo 
supplementation, neither young (8-12 week-old) nor aged (17-20 month-old) Grk3-/- mice 
show enhancement of mature trabecular bone formation in vivo (Figure 2.3A-D). Possible 
explanations of this finding may be attributed to our Grk3-/- conventional knockout mouse 
model, where there may be other compensatory cellular interactions at play. Another 
conclusion to be considered is that GRK3 deficiency within niche BmMSCs may have more 
pronounced effects on hematopoiesis as opposed to mature bone development in vivo. 
Indeed, others have shown that early mesenchymal progenitors that produce high levels of 
CXCL12 are required for hematopoietic stem cell maintenance [33] as opposed to mature 
osteoblasts, which would be supportive of this conclusion. Additionally, Grk3 expression 
levels have been found to be either undetectable or minimally expressed in osteoblastic cell 
lines and osteoblasts [121, 122], which could also explain why differences were not observed 
in trabecular bone in vivo. 
To test whether GRK3 may regulate S1P-stimulated S1PR, our studies utilized 
sphingosine kinase inhibitor (SKI) to efficiently reduce the active S1P ligand in extended 
time-course studies and thereby block ligand activation for all S1PR family members 
expressed on BmMSCs (Figure 2.4, Appendix 6 and 7). These results did show that the 
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enhanced proliferation and osteogenic differentiation of Grk3-/- BmMSCs can be reduced to 
WT levels with effective removal of the S1PR ligand. Of note, we also tested specific S1PR 
antagonism targeting S1PR1 and S1PR3 [123]. However, we observed BmMSC cellular 
toxicity in our extended time-course studies while using similar concentrations of vehicle 
(DMSO) alone that was present in the solubilized S1PR1 and S1PR3 antagonist (VPC23019, 
Cayman Chemical) group (Appendix 8). Consequently, our culture studies with BmMSCs 
and S1PR antagonism could not identify which S1PR subtype expressed on BmMSCs elicit 
the enhanced functionality due to concerns about cell viability.  
GRK3 is a ubiquitously expressed kinase that regulates a number of GPCRs, 
including parathyroid hormone receptor (PTHR) [124]. Although our cellular 
characterization studies suggest loss of GRK3 function affects S1PR signaling leading to 
enhanced BmMSC functionality ex vivo, we considered GRK3 regulation of parathyroid 
hormone/parathyroid hormone receptor (PTH/PTHR), since PTH/PTHR has been linked to 
osteoblast differentiation and enhanced hematopoiesis [37, 38]. However, ligand PTH is not 
readily available in ex vivo cultures, and PTH-R was absent from a RNA-seq database 
evaluation of readily expressed GPCRs on (human) BmMSCs (ENCODE GEO accession: 
GSE90273) [125]. Alternatively, the RNA-seq database showed S1PR expression on 
BmMSC, and it is well established that S1P is readily available in horse and fetal bovine 
serum (i.e.: BmMSC culture media) [109].  
Contrary to our finding, Hosogane et al. proposed CXCL12 regulates bone 
morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem 
cells demonstrated in part by treatment with AMD3100 (CXCR4 antagonist) to show 
reduction of osteogenic differentiation [126]. However, our data show low levels of CXCR4 
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mRNA expression detected on ex vivo murine BmMSCs (Appendix 3) and functional tests 
with CXCL12 stimulation or CXCR4 signaling inhibition with AMD3100 resulted in no 
effect (Appendix 4). While CXCR4 is readily detected on human BmMSCs [127, 128], basal 
level CXCR4 on murine BmMSCs in culture have been less readily detected [129]. Other 
possible explanations for outcome differences may be that the Hosogane et. al experimental 
sub-populations were different based on isolation and/or cell surface marker expression 
and/or differences in AMD3100 concentration.  
To investigate whether the enhanced functionalities of Grk3-/- BmMSCs were due to 
changes in downstream signaling, we tested the ERK signaling pathway since previous 
studies suggest ERK activation promotes both mesenchymal stem cell [111] and pre-
osteoblastic cell line [112] osteogenic differentiation, as well as mesenchymal stem cell 
proliferation [78]. Our previous work has shown loss of GRKs elicit sustained ERK signaling 
due to prolonged GPCR surface expression [55]; therefore, we hypothesized loss of GRK3 in 
BmMSCs may elicit sustained ERK activation through S1P/S1PR. Our results show that 
stimulation with S1P prolongs Grk3-/- BmMSC ERK1/2 signaling (Figure 2.5), and thus 
suggest S1P-ligand induced signaling of Grk3-/- BmMSCs may elicit enhanced cell functions 
mediated through the ERK1/2 signaling pathway. 
S1PR1 and S1PR3 have been shown to stimulate BmMSC function [114], and 
S1PR1-mediated enhanced proliferation has been demonstrated in adipose-derived 
mesenchymal stem cells [78]. Furthermore, since we found S1PR1 more readily expressed on 
BmMSCs compared to S1PR3 (Appendix 7), we focused our receptor signaling regulation 
studies on S1PR1 to determine whether GRK3 enhances recruitment of β-arrestin, a protein 
necessary for GPCR internalization and another pathway of GPCR regulation in addition to 
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receptor desensitization by GRKs. Previous studies have shown GRK2, which shares high 
homology with GRK3, phosphorylates the C-terminus of S1PR1 [130, 131], and activated 
S1PR1 recruits β-arrestin for receptor internalization [131, 132]. Furthermore, cells deficient 
in GRK2 have high levels of surface S1PR1 [79]. Consequently, we compared GRK2 as a 
positive control for our modified-TANGO assay. We demonstrate GRK3 enhances β-arrestin 
recruitment to the C-terminus of S1PR1, as does GRK2 (Figure 2.6A). Furthermore, our 
continued investigation shows BmMSCs deficient in GRK3 had decreased S1PR1 
internalization (i.e. more surface expression) (Figure 2.6B).  Taken together, we propose loss 
of GRK3 affects S1PR1 regulation and internalization and elicits prolonged surface receptor 
expression that may sustain late-phase ERK1/2 activation (Figure 2.5). 
 
Conclusion 
In summary, our study reveals how Grk3-/- BmMSCs have enhanced functions of 
osteogenic differentiation, CXCL12 production, and proliferation ex vivo, and our data 
suggest GRK3 regulates these functionalities through S1P/S1PR (Figure 2.7A). We 
demonstrate GRK3 recruits β-arrestin, a protein necessary for receptor internalization, to the 
C-terminus of S1PR1, and BmMSCs lacking GRK3 regulation have impaired S1PR1 
internalization and prolonged ERK1/2 signaling (Figure 2.7B). Our work suggests GRK3 






Figure 2.7. Proposed model for GRK3-deficient BmMSCs within the niche. (A) Our 
studies suggest BmMSCs deficient in GRK3 secrete more CXCL12 and proliferate more 
rapidly, which may increase support to hematopoietic stem and progenitor cell (HSPC) 
development. (B, top) We propose GRK3 desensitizes S1PR and recruits β-arrestin to 
affect ERK1/2 signaling and receptor internalization. (B, bottom) Grk3-/- BmMSCs 
have enhanced functions of proliferation and osteogenic differentiation, and this may be 
mediated through decreased S1PR1 internalization (i.e. more surface expression) and 
prolonged late-phase ERK1/2 activation. 
41 
 
CHAPTER 3: G PROTEIN-COUPLED RECEPTOR KINASE 3 REGULATES 




 Hematopoietic cell transplantation (HCT) treats malignant and non-malignant 
diseases; however, patient immune reconstitution after HCT is variable and associated with 
morbidity and mortality. Thus, HCT improvements are warranted for the enhancement of 
therapeutic outcomes. 
Hematopoietic stem cells (HSCs) are primitive cells that differentiate into all the 
hematopoietic lineages (erythroid, myeloid, lymphoid) to reconstitute the immune system 
after HCT. The goal of this study is to better understand HSC and progenitor cell function. 
Mice deficient in G protein-coupled receptor kinase 3 (GRK3), an intracellular kinase that 
regulates G protein-coupled receptors, have a hypercellular bone marrow with increased 
hematopoietic stem-progenitor cells (HSPCs) and oligopotent progenitors, as well as 
increased leukocytes in the blood. We hypothesize GRK3 regulates bone marrow HSPC 
numbers and thus, impacts hematopoiesis. We predict if GRK3 is absent, then HSPC 
numbers will increase, which may positively influence HCT.
                                                             
3The work in chapter 3 has not been submitted or published as a research manuscript. The project work is ongoing. 
Contributors to this project include: Brozowski JM, Timoshchenko RG, Serafin DS, and Tarrant TK. 
 
Figure 3.1 reused with copyright permission granted by FASEB/Journal of Leukocyte Biology on November 8, 
2017. JM Brozowski made illustration Figure 3.2 and performed experiments for Figure 3.3 (JMB, DSS), Figure 
3.4, Figure 3.5 (TKT, RGT, JMB), Figure 3.6, Figure 3.7 and appendices 9-12. 
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To test whether GRK3 deficiency enhances hematopoietic cell function in vivo, we 
utilized a short-term transplantation assay, termed colony forming unit-spleen (CFU-S) assay. 
In the CFU-S assay, transplanted HSPCs with self-renewal capabilities form clonal colonies 
on the spleen, which can be enumerated to measure extramedullary hematopoiesis. Our data 
suggest hematopoiesis of GRK3-deficient (Grk3-/-) HSPC is enhanced since transplanted 
Grk3-/- Lin- Sca1+ c-Kit+ (LSK) HSPCs or Grk3-/- whole bone marrow increase colony 
counts on the explanted spleen in comparison to wildtype (WT) controls. 
Our previous studies have demonstrated GRK3 regulates CXCL12/CXCR4 signaling 
interactions and functional outcomes on mature hematopoietic cells. Since CXCR4 is highly 
expressed on HSCs, common myeloid progenitors (CMPs), granulocytic monocytic 
progenitors (GMPs), and B cells (cells also increased in number in our Grk3-/- mouse), we 
tested whether Grk3-/- HSPCs would have increased colony counts when grown in these 
lineage-specific pathways, and if it was dependent upon CXCL12/CXCR4 interactions. We 
utilized the well established ex vivo colony forming unit-granulocytic and monocytic (CFU-
GM) and -pre-B (CFU-Pre-B) assays to assess numbers and types of progenitor colony 
formations in standard growth conditions and in the presence of CXCR4 agonist (CXC12) 
and antagonist (AMD3100). Both Grk3-/- hematopoietic myeloid and lymphoid colony 
counts ex vivo increased with CXCR4 ligand stimulation (CXCL12), and Grk3-/- CFU-GM 
colony counts reduced to WT levels with CXCR4 antagonist treatment (AMD3100). 
Taken together, our in vivo and ex vivo CFU data suggest GRK3 regulates bone 
marrow HSPC numbers, and this is at least in part, mediated through CXCL12/CXCR4 
stimulation. Given the positive correlation between the stem cell graft CFU colony counts 
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and the success rate of immune reconstitution after HCT, we propose the enhanced CFU 
readouts from Grk3-/- HSPCs may positively influence HCT. 
 
Significance Statement 
  HCT is a treatment used to replenish the immune system by transferring donor 
hematopoietic cells into an immunologically-destroyed irradiated recipient. Erythroid and 
myeloid reconstitution occurs within weeks; however, lymphoid lineage reconstitution may 
be delayed for years after HCT. The delayed immune reconstitution jeopardizes 
immunologically compromised patients and makes them vulnerable to opportunistic 
infections. The delay in immune reconstitution may benefit from increased stem cell 
numbers, enhanced stem cell proliferation, or improved stem cell homing, all of which 
potentiate cellular engraftment and hematopoiesis. Potentiated hematopoiesis and stem cell 
engraftment is demonstrated by Grk3-/- HSPCs— specifically since transplanted Grk3-/- 
HSPCs have increased CFU numbers. We further show Grk3-/- CFU numbers can be 
affected through CXCR4 agonist and antagonist treatment. Thus, we propose GRK3 




HCT treats hematological cancers, immune deficiencies, autoimmunity, and other 
diseases by replacing the patients’ compromised immune system with a functional immune 
system [133]. Replenishing the immune system is possible since the transplanted HSCs, 
which differentiate into the erythroid, myeloid, and lymphoid hematopoietic lineages, are 
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self-renewing and reconstitute the immune system through proliferation and differentiation 
after HCT. Erythrocyte, granulocyte, monocyte, and megakaryocyte/platelet lineage 
reconstitution takes place within the first weeks after HCT; however, complete immune 
reconstitution of the B and T lymphocytes can be delayed for years after transplantation [134, 
135]. Delayed immune reconstitution compromises the immune system and increases patient 
susceptibility to opportunistic infections. Therefore, the effectiveness of HCT is variable and 
associated with morbidity and mortality.  
Understanding stem cell function may identify mechanisms to improve immune 
reconstitution after HCT. Cellular engraftment from HCT may be affected by increased stem 
cell numbers, enhanced stem cell proliferation, or improved stem cell homing [136]. 
Therefore, we propose immune reconstitution after HCT may benefit from increased stem 
cell numbers, enhanced stem cell proliferation, or improved stem cell homing. Since Grk3-/- 
mice have increased HSPC numbers in the bone marrow and increased numbers of 
leukocytes in the blood, we aimed to examine the effects of GRK3 on HSPC function and 
engraftment in models of HCT.  
Engraftment and hematopoiesis of HSPCs occur in the bone marrow 
microenvironment, termed niche, or also in extramedullary hematopoietic sites such as the 
spleen. The niche supports HSPC development by interactions with the niche stromal 
mesenchymal stem cells, osteoblasts, and CXCL12-abundant reticular (CAR) cells, which 
secrete soluble factors, importantly chemokine CXCL12 [32, 33]. CXCL12 is a ligand for 
GPCR CXCR4 on HSPCs and involved in stem cell retention, migration, and proliferation 
functionality [31, 137]. We and others have demonstrated that CXCR4 on mature 
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hematopoietic cells is regulated by GRK3 [55, 106]; however, it is unknown whether GRK3 
has a functional effect mediated by CXCR4 on HSPCs. 
 We observed Grk3-/- mice, in comparison to wildtype (WT) control mice, have 
increased total white blood cells in the peripheral blood and a hypercellular bone marrow 
with increased LSK HSPCs and oligopotent progenitors [55]. Therefore, we hypothesize 
bone marrow HSPC numbers are regulated by GRK3 and mediated through 
CXCL12/CXCR4 interactions, and we predict absence of GRK3 increases CXCL12/CXCR4 
function resulting in increased numbers of HSPCs. 
 
Materials and Methods 
Animals.  
Wildtype (WT) C57BL/6 and GRK3-deficient (Grk3-/-) age-matched (8-12 week-
old) mice were used under standard IACUC-approved protocols in the AAALAC-accredited 
vivarium of UNC, and care of animals was in accordance with institutional guidelines. The 
Grk3-/- mouse strain was provided by Dr. Robert J. Lefkowitz (Duke University) and 
backcrossed >12 generations on the C57BL/6 background. 
 
Flow cytometry bone marrow lineage analyses.  
Femur and tibia of WT and Grk3-/- mice at 8-12 weeks were crushed using mortar 
and pestle for bone marrow extraction. After red blood cell (RBC) lysis, white blood cells 
(WBCs) were counted using hemocytometer and trypan blue exclusion to obtain a total bone 
marrow cell count. WBCs were stained with anti-CD3, CD4, CD8, Ter119, CD45R (B220), 
Ly-6G, CD11b (PE-Cy5) for lineage positive exclusion and stained for experimental marker 
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analysis of c-Kit (APC-e780, clone 2B8), Sca1 (PE-Cy7, clone D7), CD34 (FITC, clone 
RAM34), CD16/CD32 (PE, clone 93), CD150 (Pacific Blue, clone TC15-12F12.2 
Biolegend), CD48 (FITC, clone HM48-1), and Interleukin-7 receptor-α (PE, IL-7Rα, clone 
A7R34) and acquired on the LSRII or CYAN. All antibodies were purchased from 
eBioscience unless otherwise noted. Appropriate isotype controls for each marker were 
analyzed and used to set gates using FlowJo version X. Hematopoietic stem and progenitor 
populations were identified using markers and gating strategies previously published (LT-
HSC [18-20], ST-HSC [18, 21], LSK HSPC/CMP/GMP/MEP [138], CLP [139-141]). 
 
In vivo colony forming unit-spleen (CFU-S) assays.  
For LSK HSPC transplants, recipient mice were irradiated with 950 rads (9.5 Gy) 
with a split dose and rested at least 3 hours. Donor bone marrow was flushed, RBCs lysed, 
and depleted of lineage positive cells via EasySepTM mouse hematopoietic progenitor cell 
isolation kit (19856, Stem Cell Technologies). Lin- cells were stained with c-Kit (PE, clone 
2B8 eBioscience) and Sca1 (APC, clone D7, eBioscience) for at least 30 minutes and sorted 
using the MoFlo or MoFlo XDP cytometer. Cells were injected by tail vein of 0.1 cc (200 
LSK HSPCs in DPBS). Mice were treated with Sulfamethoxazole/Trimethoprim in water 
supply (antibiotic water) until assay endpoint. Spleens were fixed on day 12 in Telly’s 
fixative and nodule colony formations were counted. 
For whole bone marrow transplants, recipient mice were irradiated with 1,000 rads 
(10 Gy) and rested 4-6 hours. Donor bone marrow was flushed, RBCs lysed, and washed 
with DPBS. Cells were injected by tail vein of 0.1 cc (5x104 cells in DPBS). Spleens were 
fixed on day 8 in Telly’s fixative and nodule colony formations were counted.  
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Ex vivo colony forming unit-granulocytic and monocytic (CFU-GM) progenitor cell 
assay. 
Methocult (GM-M3534, Stem Cell Technologies) was supplemented with mouse 
CXCL12 (Shenandoah) at 50 ηg/mL alone or in combination with AMD3100 (Sigma) at 
1,000 ηg/mL in conical tubes, and 300 µL of 1x105 bone marrow cells/mL were added to 3 
mL of methocult and vortexed for 10 seconds to ensure thorough mixing of cells into the 
viscous methocult reagent. Methocult (containing cells) was plated onto 35mm2 petri dishes. 
Plates were incubated at 37°C at 5% CO2. Colonies were counted on day 12, as per 
manufacturer’s instructions. 
 
Ex vivo colony forming unit-pre-B (CFU-Pre-B) progenitor cell assay.  
Methocult (M3630, Stem Cell Technologies) was supplemented with mouse CXCL12 
(Shenandoah) at 50 ηg/mL alone or in combination with AMD3100 (Sigma) at 1,000 ηg/mL 
in conical tubes, and 300 µL of 2x106 bone marrow cells/mL were added to 3 mL of 
methocult and vortexed for 10 seconds to ensure thorough mixing of cells into the viscous 
methocult reagent. Methocult (containing cells) was plated onto 35mm2 meniscus-free petri 
dishes (SmartDishTM, Stem Cell Technologies). Plates were incubated at 37°C at 5% CO2. 
Colonies were counted on day 7, as per manufacturer’s instructions. 
 
Statistical analyses.  
All data were graphed utilizing GraphPad Prism v.7 and statistically evaluated using 
GraphPad Prism. Student’s t-test compared two independent groups (WT and Grk3-/-) for 
subset bone marrow lineage analyses via flow cytometry, LSK HSPC CFU-S transplant, and 
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whole bone marrow CFU-S transplant assays. Taking into consideration strain (WT and     
Grk3-/-) and multiple treatment groups, the CFU-GM and CFU-Pre-B assays were 




Grk3-/- HSPC and oligopotent progenitor cell numbers are increased within the bone 
marrow.  
  In a previous study, we observed Grk3-/- mice have a hypercellular bone marrow 
with increased numbers of total bone marrow cells ([55], Figure 3.1B, C). A basic subset 
analysis showed significantly increased LSK HSPCs and oligopotent progenitors ([55], 
Figure 3.1D). Here, we expanded our lineage subset analyses (Figure 3.2) to include short-
term HSCs (ST-HSCs), myeloid progenitor population (MPPs), and common lymphoid 
progenitors (CLPs). Due to the varying views on what parent population CLPs may originate 
[139-141], we evaluated CLPs that are believed to arise from LSK HSPC population, as well 
as those believed to arise from the Lin- Sca1lo c-Kitlo population. Our preliminary findings 
suggest Grk3-/- mice have an increase trend of total numbers of LSK HSPCs (Figure 3.3A), 
common myeloid progenitors (CMPs) and granulocytic monocytic progenitors (GMPs) 
(Figure 3.3B), reflective of our previous report ([55], Figure 3.1D). However, our expanded 
subset analyses also showed an increase trend in total numbers of MPPs (Figure 3.3B), 
Sca1lo c-Kitlo cells ((Figure 3.3C) and CLPs (Figure 3.3C, D). However, long-term HSCs 
(LT-HSCs) and ST-HSCs were comparable between WT and Grk3-/- mice (Figure 3.3A), 
suggesting GRK3 may play a more pertinent role on HSPCs than the most primitive LT- and 
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ST-HSCs. Interestingly, the percent of populations remained comparable throughout all 




Figure 3.1. G protein-coupled receptor kinase 3 deficient (Grk3-/-) mice 
have enhanced hematopoiesis. Representative femur bone marrow 
histopathology from (A) WT and (B) Grk3-/- mice (40X). (C) Total viable 
bone marrow cell numbers counted with trypan blue exclusion. Data 
represent mean ± SEM, n=14 (WT) and n=13 (Grk3-/-). (D) Enumeration of 
bone marrow-derived lineage negative (Lin-) hematopoietic cell subsets. 
Data represent mean ± SEM, n=13 (WT) and n=12 (Grk3-/-). LSK: Lin− 
Sca1+ c-Kit+; LT-LSK (LT-HSC): Lin− Sca1+ c-Kit+ CD48− CD150+; GMP: 
Lin− Sca1− c-Kit+ CD16/32+ CD34+; CMP: Lin− Sca1− c-Kit+ CD16/32− 
CD34+. (E) Peripheral blood analysis enumerating leukocyte subsets from 
WT and Grk3-/- mice using leukocyte markers CD45+ and further subset 
identification with B220+ (B cells), CD3 (T cells), and Ly-6G (neutrophils). 
Data represent mean ± SEM, n=23 (WT) and n=25 (Grk3-/-). * P<0.05  
** P<0.01 *** P<0.001 Figures from Tarrant et al. J Leukoc Biol. 2013 
Dec; 94(6): 1243-1251. Copyright © 2013 Society for Leukocyte Biology. 
Reused with copyright permission. Figure editing (re-arrangement only) 
permission granted by corresponding author. 
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Transplantation of Grk3-/- LSK HSPCs increases hematopoietic stem cell colonies on 
the spleen.  
Since cellular engraftment from HCT may be improved by increased stem cell 
numbers, proliferation, and/or homing [136], and our flow cytometry data suggest GRK3 
deficiency affects the hematopoietic hierarchy (Figure 3.2) with increased numbers of LSK 
HSPCs (Figure 3.1D and 3.3A), we wanted to further test whether GRK3 deficiency 
specifically enhances LSK HSPC function in vivo. Thus, we utilized the short-term 
transplantation assay, termed colony forming unit-spleen (CFU-S) assay. Unlike humans, 
mice commonly undergo both hematopoiesis within the bone marrow and extramedullary 
Figure 3.2. Hematopoietic hierarchy of stem and progenitor cell differentiation 
within the bone marrow. Long-term hematopoietic stem cell (LT-HSC); Short-term 
hematopoietic stem cell (ST-HSC); Lineage negative (Lin-) Sca1+ c-Kit+ 
hematopoietic stem-progenitor cell (includes LT-HSC and ST-HSC); Myeloid 
progenitor population (MPP); Common myeloid progenitor (CMP); Granulocytic 
monocytic progenitor (GMP); Myeloid erythroid progenitor (MEP); Common 
lymphoid progenitor (CLP). 
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sites, such as the spleen. Due to murine extramedullary hematopoiesis in the spleen, 
transplanted cells with self-renewal capabilities home to the spleen and form clonal colonies, 
which can be easily visible and enumerated by eye.  In the CFU-S assay, a single cell is 
responsible for each spleen colony, suggesting the transplanted cells undergo self-renewal 
and expansion [6]. Therefore, there is a linear relationship between the number of 
Figure 3.3. Grk3-/- hematopoietic stem and progenitor cell numbers are 
increased within the bone marrow. (A) Total cell numbers of hematopoietic stem 
cells, (B) myeloid progenitors, (C,D) lymphoid progenitors from WT and Grk3-/- 
femurs enumerated by flow cytometry. Data represent mean ± SEM, n=8. * P<0.05 
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transplanted cells and the colony spleen count [6]. However, when we transplanted identical 
numbers of donor WT or Grk3-/- LSK HSPCs into WT recipient mice, the Grk3-/- LSK 
HSPC donor group had increased stem cell colony counts on the spleen at day 12, in 
comparison to the WT LSK HSPC donor group (Figure 3.4). 
 
 
Transplantation of Grk3-/- bone marrow cells increases hematopoietic progenitor 
colony counts on the spleen.  
Interestingly, spleen colonies evident at earlier timepoints are believed to be derived 
from progenitors rather than from HSPCs, which present at later timepoints [142]. Since our 
subset analysis data demonstrated Grk3-/- mice had increased HSPCs and oligopotent 
progenitor cells, we wanted to next test whether GRK3 deficiency specifically enhances 
Figure 3.4. Transplantation of Grk3-/- LSK HSPCs increases hematopoietic 
stem cell colonies on the spleen. Colony forming unit-spleen (CFU-S) assay day 
12 harvest selectively measures individual HSC homing to the spleen and 
proliferation. Each dot represents the number of colonies on the spleen of one 
mouse. Data represent mean ± SEM, n=12 (WT) and n=25 (Grk3-/-). * P<0.05 
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progenitor cell function in vivo. When we transplanted identical numbers of donor WT or 
Grk3-/- bone marrow cells into WT recpients, the Grk3-/- donor group had increased 
progenitor colony counts on the spleen at day 8, in comparison to WT donors (Figure 3.5). 
 
CXCL12 stimulation increases hematopoietic granulocytic and monocytic-GM 
progenitor colony formation (CFU-GM) of Grk3-/- bone marrow cells.  
Our results thus far suggest Grk3-/- mice have enhanced hematopoiesis in the bone 
marrow (Figure 3.1 and 3.3) and transplantation of Grk3-/- LSK HSPCs or whole bone 
marrow increase HSPC numbers on the spleen (Figure 3.4 and 3.5); however, the 
mechanism of the observed phenotype is undefined. Since (1) previous findings demonstrate 
GRK3 regulates CXCL12/CXCR4 on mature hematopoietic cells [55], and (2) CXCR4 is 
highly expressed on HSCs, CMPs, GMPs, and B cells [61], we hypothesized GRK3 may be 
regulating CXCL12/CXCR4 on immature hematopoietic cells to induce this phenotype. 
Figure 3.5. Transplantation of Grk3-/- bone marrow cells increases hematopoietic 
progenitor colony counts on the spleen. (A) Colony forming unit-spleen (CFU-S) assay 
day 8 harvest selectively measures hematopoietic progenitor cell homing to the spleen 
and proliferation. Each dot represents the number of colonies on the spleen of one mouse. 
(B) Representative images demonstrating that each colony or “white nodule” arose from 
a single self-renewal cell. Data represent mean ± SEM, n=16 (WT) and n=22 (Grk3-/-).  




Therefore, we utilized the well established ex vivo colony forming assay to assess myeloid 
colony formation (CFU-GM) in the presence of CXCR4 agonist CXCL12 (concentration 
curve available in Appendix 10A) and CXCR4 antagonist AMD3100. Our results 
demonstrate Grk3-/- granulocytic and monocytic colony counts were increased upon 
CXCL12 stimulation and decreased to WT levels upon treatment with AMD3100 (Figure 
3.6), suggesting the enhanced numbers of Grk3-/- myeloid progenitors is mediated, at least in 
part, through regulation of CXCL12/CXCR4.  
 
CXCL12 stimulation increases hematopoietic lymphoid pre-B cell colony formation 
(CFU-Pre-B) of Grk3-/- bone marrow cells.  
Next, we tested whether GRK3 regulation of CXC12/CXCR4 is responsible for the 
enhanced lymphoid progenitor numbers by utilizing the well established ex vivo colony 
Figure 3.6. CXCL12 stimulation increases hematopoietic granulocytic 
and monocytic-GM progenitor colony formation (CFU-GM) of Grk3-/- 
bone marrow cells. Cells treated with ligand for CXCR4 (CXCL12, 50 
ηg/mL) or both CXCL12 and antagonist for CXCR4 (AMD3100, 1,000 
ηg/mL). Data represent mean ± SEM, n=3. ** P<0.01  *** P<0.001 
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forming assay to assess pre-B lymphoid colony formation (CFU-Pre-B) in the presence of 
CXCR4 agonist CXCL12 (concentration curve available in Appendix 10B) and CXCR4 
antagonist AMD3100. Our results revealed Grk3-/- pre-B colony counts were slightly 
increased upon CXCL12 stimulation and decreased with treatment of AMD3100, albeit not 
to a WT level (Figure 3.7), suggesting the enhanced numbers of Grk3-/- pre-B lymphoid 
progenitors may also be mediated, at least in part, through CXCL12/CXCR4 stimulation. We 
also observed CXCR4 antagonist treatment with AMD3100 inhibited the size (clonal 
proliferation) of the WT and Grk3-/- CFU-Pre-B colonies, though at comparable rates 
(Appendix 11). Interestingly, we have also previously shown Grk3-/- mice have increased 
numbers of mature B cells in the blood (Figure 3.1E), suggesting GRK3-deficiency may 
potentiate B cell lineage development; a process often delayed after HCT. 
 
 
Figure 3.7. CXCL12 stimulation increases hematopoietic lymphoid pre-B cell 
colony formation (CFU-Pre-B) of Grk3-/- bone marrow cells. Cells treated with 
ligand for CXCR4 (CXCL12, 50 ηg/mL) or both CXCL12 and antagonist for CXCR4 




 HCT is the transfer of a stem cell graft to a patient whom has undergone 
myeloablative conditioning, i.e.: destruction of their immune system via irradiation. The stem 
cell graft (from bone marrow, peripheral blood or umbilical cord blood sources) contains 
HSCs that reconstitutes the patients’ immune system. Although this clinical approach is used 
to treat various hematological malignancies and non-malignant diseases, HCT is also 
associated with morbidity and mortality due to toxicities, graft-versus-host disease, and 
infection [143]. HCT patients experience low levels of red blood cells, white blood cells, and 
platelets, termed pancytopenia, that lasts days to weeks after transplantation. Neutrophils are 
the first immune subset to recover within 2-4 weeks, followed by monocytes, natural killer 
cells, platelets, and RBCs, respectively. Interestingly, lymphocyte recovery can take months 
to years with initial recovery of CD8 T cells within 2-8 months, followed by B cells and then 
CD4 T cells. Thus, HCT patients are susceptible to opportunistic infections for at least one-
year post-HCT due to the delay in immune reconstitution [143]. 
It is well established that immune reconstitution and successful patient HCT 
outcomes are contingent upon the number and quality of transplanted HSCs, which need to 
migrate to, engraft in, and repopulate the bone marrow [136]. Therefore, identifying 
therapeutic strategies that may increase stem cell numbers, migration, or proliferation, may 
enhance cellular engraftment and thus, immune reconstitution. 
The G protein-coupled receptor (GPCR) CXCL12/CXCR4 pathway is the most 
essential chemotactic signaling mechanism involved in HSPCs [136, 144-146]. Bone marrow 
niche cells secrete CXCL12, which facilitate HSPC homing to the bone marrow via CXCR4; 
however, after myeloablative conditioning, CXCL12 expression is extremely low due to the 
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proteolytic environment. Therefore, there have been attempts to target and enhance 
CXCL12/CXCR4 chemotaxis, such as through ex vivo treatment of HSPCs with heat or 
prostaglandin E2 (PGE2) that both increase CXCR4 expression, and PGE2 also enhances 
HSPC proliferation [147, 148]. Such studies have demonstrated manipulation of 
CXCL12/CXCR4 may enhance the functional quality of HSPCs. 
Our previous studies have demonstrated GRK3, an intracellular kinase that 
phosphorylates GPCRs to desensitize the receptor for internalization, specifically regulates 
CXCL12/CXCR4 cellular functions on mature hematopoietic cells [55]. Furthermore, we 
observed mice deficient in GRK3 have a hypercellular bone marrow with increased HSPCs 
and oligopotent progenitors, as well as increased leukocytes in the blood ([55], Figure 3.1, 
Figure 3.3), suggesting GRK3 deficiency may enhance HSPC function in vivo.  
Here, we demonstrate transplantation of Grk3-/- LSK HSPCs increases hematopoietic 
stem cell colonies on the spleen and transplantation of Grk3-/- bone marrow increases 
hematopoietic progenitor colonies on the spleen (colony forming unit-spleen, CFU-S) 
(Figure 3.4 and 3.5). Due to the positive correlation between the stem cell graft CFU colony 
counts and the success rate of immune reconstitution, our preliminary findings suggest 
GRK3 deficiency may positively influence HCT through enhanced immune reconstitution. 
Similar findings were evident when HSPCs were treated with valporic acid, a histone 
deacetylase inhibitor, which also induced increased spleen colony formations and 
demonstrated enhanced HSPC engraftment, which is believed to be mediated through 
increased surface expression of CXCR4 and cellular proliferation [149]. Likewise, our 
previous study demonstrated hematopoietic cells deficient in GRK3 had sustained CXCR4 
surface expression and enhanced migration to CXCL12 [55]. Therefore, while we 
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acknowledge GRK3 deficiency enhances spleen colony numbers, we recognize we have not 
addressed whether this may be due to enhanced homing and/or in vivo proliferation, which 
will need to be further evaluated. 
Since CXCL12/CXCR4 is an essential signaling mechanism involved in HSPC 
function, we tested whether the increased Grk3-/- bone marrow numbers were due to the 
CXCL12/CXCR4 pathway. Using ex vivo CFU assays, we assessed number and types of 
oligopotent progenitor cells within our WT and Grk3-/- bone marrow. Our results suggest 
Grk3-/- bone marrow enhances hematopoietic myeloid (granulocytic and monocytic-GM 
progenitors) (Figure 3.6) and lymphoid (pre-B progenitors) (Figure 3.7) colony counts 
mediated via CXCL12/CXCR4 stimulation. Interestingly, we have also previously shown 
Grk3-/- mice have increased numbers of mature B cells in the blood (Figure 3.1E), 
suggesting GRK3 deficiency may potentiate B cell lineage development; a process often 
delayed after HCT.  
Lastly, to test whether there may be potential differentiation-bias among WT or  
Grk3-/- bone marrow cells, all bone marrow subset percentages were also evaluated 
(Appendix 9), which showed comparable percentages among WT and Grk3-/- mice, 
suggesting no lineage skewing, just overall increased cell numbers. Further, we tested 
potential differentiation-bias in vitro by culturing LSK HSPCs in lineage-specific CFU 
culture conditions, though again, progenitor colony counts were comparable between WT 







 In summary, our preliminary work thus far implicates the importance of GRK3 on 
HSPC function. Specifically, Grk3-/- hematopoietic cells result in increased HSPC CFU 
numbers. Further, we have demonstrated the increase of Grk3-/- HSPC numbers may be 
mediated through CXCL12/CXCR4. Due to the positive correlation between the CFU 
content of a stem cell graft and the success rate of immune reconstitution after HCT, we 




CHAPTER 4: CONCLUSION AND FUTURE DIRECTIONS 
 
Overview 
The clinical utilization of hematopoietic cell transplantation (HCT) beginning in the 
1950s combined with the scientific discoveries by Till, McCulloch, Friedenstein, and 
Schofield aided our initial understanding of the importance of the bone marrow 
microenvironment and the essential molecular and cellular interactions to support 
hematopoiesis. Subsequent cellular studies over the past 60 years have defined the intricacy 
of the niche, in large part due to the advancements in gene targeting and knockout murine 
models through homologous recombination techniques developed by Drs. Oliver Smithies, 
Mario Capecchi, and Martin Evans (Nobel Prize in Physiology and Medicine in 2007) [150]. 
We now have a clearer understanding of the defined regions within the niche, key inhabitants 
of each region, and their influence on directing hematopoiesis. Further molecular 
understanding of GPCR interactions have also led to therapies that improve HCT as a clinical 
therapy. While knowledge in the bone marrow/hematopoietic niche field has progressed over 
the last few decades, intracellular signaling and regulation of the complex cellular 
interactions within the niche is still evolving. 
This dissertation initiated investigations to determine whether GRK3, an intracellular 
protein kinase that regulates GPCR signaling, modulates the function of BmMSCs and 
HSPCs since both cell subsets express relevant GPCRs involved in hematopoiesis. Our work 
suggests GRK3 impacts both BmMSC (Chapter 2) and HSPC (Chapter 3) function, and here,
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I discuss the implications of this work and propose future experimental directions of each 




BmMSCs are known to play an essential physiological role in the support of 
hematopoietic cell development, and yet interestingly, BmMSCs are not currently utilized in 
the United States to treat any human diseases. While promising pre-clinical HCT studies 
have shown BmMSCs transplanted with HSCs enhance hematopoietic cell engraftment 
[151], there has only been one clinical trial completed (and one recently registered as of 
October of this year) investigating the use of mesenchymal stem cells to aid immune 
reconstitution and engraftment in HCT. One interpretation of this observation is there is a 
significant knowledge gap in intracellular signaling, function, and regulatory mechanisms of 
BmMSCs that needs to be addressed before BmMSCs can advance as a cellular therapy for 
humans. Our work elucidates further understanding of how BmMSC function may be 
regulated through molecular mechanisms that enhance BmMSC cell functionality, 
specifically the importance of GRK3 regulation of S1P-activated S1PR. We show deficiency 
of GRK3 in the presence of S1P increases BmMSC proliferation and CXCL12 production, as 
well as further enhances differentiation into osteoblast precursors that support hematopoietic 
development as described in Chapter 1. Thus, the data presented in Chapter 2 serve as a 
strong foundation to test whether GRK3 deficiency in BmMSC has direct effects on 




Conclusion and future directions. 
BmMSCs isolated from GRK3-deficient (Grk3-/-) mice have enhanced proliferation, 
osteogenic differentiation ex vivo, and higher levels of CXCL12 compared to wildtype (WT) 
BmMSCs in identical culture conditions and passages. Given the vital role of BmMSCs and 
CXCL12 in supporting hematopoietic development, we found these initial findings 
interesting since they correlated with a previous observation that Grk3-/- mice have increased 
hematopoietic cell numbers isolated from the bone marrow; however, this dissertation 
research focused on understanding how GRK3 regulated the function of BmMSCs by 
identifying the signaling mechanism(s) through which it may be acting. Therefore, a future 
goal would be to determine whether Grk3-/-  BmMSCs indeed directly impacts 
hematopoiesis. Our short-term goal is to test this by measuring HSC/HSPC numbers in an ex 
vivo co-culture system of WT HSC/HSPCs incubated with either Grk3-/- BmMSCs (or WT 
BmMSCs as control). The HSC/HSPCs will form proliferative clusters, termed colonies, on 
the stromal BmMSCs. Both colonies and total HSC/HSPCs can be enumerated after co-
incubation to determine whether Grk3-/- BmMSCs provide a proliferative advantage for the 
neighboring HSC/HSPC. Our long-term goal is to directly test whether Grk3-/- BmMSCs 
impact hematopoiesis in vivo by utilizing a conditional knockout model Grk3flox Prx1Cre, 
which will delete GRK3 from the mesenchymal lineage; however, this mouse model does not 
currently exist and will need to be generated. 
The mechanism by which GRK3 deficiency elicits higher levels of CXCL12 
compared to WT BmMSCs in identical culture conditions and passages has yet to be 
elucidated, and serves as another future direction. Due to the cross-talk mechanisms 
previously described by Golan et al. whereby S1P stimulation induces CXCL12 secretion 
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from BmMSCs [83, 84], we tested whether SKI treatment (reduction of S1P) could reduce 
CXCL12 levels in Grk3-/- BmMSC culture supernatants; however, our findings suggest at 
early timepoints (Day 1 and Day 2) Grk3-/- BmMSC CXCL12 levels were not reduced upon 
SKI treatment. Interestingly, CXCL12 levels were reduced at later timepoints upon SKI 
treatment, though this coincides with similar timepoints when SKI reduced proliferation, 
suggesting a reduction in cell number may be a contributing factor to the reduction of 
CXCL12 with SKI treatment (Appendix 13). Therefore, a short-term goal is to test whether 
higher levels of CXCL12 is possibly independent of S1P/S1PR and is simply due to 
increased cell number. To address this, we plan to harvest supernatants for CXCL12 
quantification and perform cell counts per well. This new approach of dividing CXCL12 by 
cell number will create a ratio of CXCL12 produced per BmMSC for a more direct analysis. 
Interestingly, while GRK3 deficiency elicited an enhanced osteogenic phenotype ex 
vivo, we did not see an enhanced trabecular bone volume fraction in vivo. However, this did 
not come as a surprise, since there is support to suggest perivascular niche BmMSCs that aid 
hematopoietic development may be functionally different than BmMSCs that migrate to the 
bone surface and differentiate into osteoblasts [45]. Thus, GRK3 deficiency in niche 
BmMSCs may have a more pronounced effect on hematopoiesis as opposed to mature bone 
development in vivo. Alternatively, since our studies utilized a conventional knockout murine 
model, it is possible that other cells in the bone marrow niche may be affected by GRK3 
deficiency and act as a compensatory cellular interaction, such as osteoclasts that have 
prevalent GRK3 expression [121]. This can also be tested by utilizing our proposed 
conditional GRK3 knockout mouse model (Grk3flox Prx1Cre), which would limit GRK3 
deficiency to only the mesenchymal lineage. 
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Our mechanistic studies revealed that both Grk3-/- BmMSC proliferation and 
osteogenic differentiation were reduced to WT level upon reduction of S1P, and Grk3-/- 
BmMSCs have sustained ERK1/2 signaling upon stimulation of S1PR with S1P in 
comparison to WT BmMSCs. This supports our conclusion that S1P-ligand stimulation and 
downstream MAPK activation is essential for our observed Grk3-/- phenotype. However, due 
to limitations with antagonist treatments (i.e.: cellular toxicity of vehicle), we have yet to 
define mechanisms of action on specific BmMSC-expressed S1PR subtypes (i.e.: S1PR1, 
S1PR2, S1PR3). Future short-term goals will utilize shRNA technology targeting specific 
receptor subtypes S1PR1-3 to test what specific BmMSC-expressed S1PR subtype may be 
responsible for the enhanced functionality. shRNA technology has already been successful in 
reducing Grk3 expression in these primary BmMSCs, so we do not anticipate technical 
difficulties achieving knocked-down expression; however, a potential pitfall could be that 
knocking-down important S1PR subtypes could affect cell viability. If so, alternatively, we 
can test whether over-expression of particular S1PR subtypes in WT BmMSCs during 
functional assays will elicit a similar “GRK3-deficient-like” phenotype. Identifying the S1PR 
responsible for the enhanced Grk3-/- BmMSC phenotype will provide further understanding 
of the intracellular signaling, function, and regulation to potentially aid future therapeutic 
investigations. 
In summary, our future directions aim to (1) test whether Grk3-/- BmMSCs enhance 
hematopoiesis through both ex vivo and in vivo analyses, (2) define the mechanism by which 
GRK3 deficiency elicits higher levels of CXCL12, and (3) identify the S1PR subtype that 







HCT-related mortality has been reduced by almost 10% from the 1990s to the 2000s 
[152]; however, there is still a high risk of complications in the early weeks to months 
following HCT. The HCT recipient is immunocompromised until HSCs engraft and 
differentiate into the hematopoietic lineages necessary for establishment of the new immune 
system, termed immune reconstitution. Stem cell graft failure is a complication evident in    
5-6 % of allogeneic transplants, where patients experience sustained pancytopenia—
reduction of red blood cells, white blood cells, and platelets [153] due to insufficient quality 
and numbers of transplanted HSCs [136, 154] and/or immune-related complications, such as 
infections and graft-versus-host disease. Interestingly, the rate of engraftment positively 
correlates with the numbers of HSCs transplanted [154], suggesting immune reconstitution 
after HCT may benefit from increased stem cell numbers, as well as improved quality of 
stem cell function, such as enhanced homing and proliferation. Our work described within 
Chapter 3 suggests GRK3 deficiency not only increases numbers of multipotent HSPCs in 
vivo, but also increases numbers of oligopotent progenitors and importantly, mature 
lymphoid cells—the last hematopoietic lineage to develop in the transplanted recipient. 
Furthermore, GRK3 deficiency increases in vivo and ex vivo colony forming units (CFUs), 
mediated at least in part through CXCL12/CXCR4 stimulation. Taken together, given the 
positive correlation between HSC numbers and CFU colony counts within the stem cell graft 
and the success rate of engraftment and immune reconstitution after HCT, respectively, we 
propose the work within Chapter 3 provides a foundation for future directions to test 
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mechanistically how GRK3 deficiency improves stem cell function and determine whether 
such enhanced functions improve engraftment and immune reconstitution after HCT. 
 
Conclusion and future directions. 
Grk3-/- mice have a hypercellular bone marrow with increased HSPCs and 
oligopotent progenitors, as well as increased leukocytes in the blood, suggesting GRK3 
deficiency enhances hematopoiesis. However, several different cell types can contribute to 
this phenotype in a conventional knockout murine model. As such, Chapter 2 investigated the 
role of GRK3 deficiency on BmMSC function, and Chapter 3 focused on the role of GRK3 
deficiency on HSPC function. 
To investigate whether GRK3 deficiency in HSC/HSPCs enhances hematopoietic cell 
function within the in vivo transplantation setting, we utilized a short-term transplantation 
assay, termed colony forming unit-spleen (CFU-S) assay. In the CFU-S assay, transplanted 
HSPCs with self-renewal capabilities form clonal colonies (CFUs) on the spleen that can be 
enumerated to measure extramedullary hematopoiesis. Interestingly, transplanted Grk3-/- 
Lin- Sca1+ c-Kit+ (LSK) multipotent HSPCs had increased CFUs on the explanted spleen at 
day 12 in comparison to WT controls. Next, to determine whether oligopotent progenitors 
from   Grk3-/- mice had increased functionality in vivo, we transplanted whole bone marrow 
and showed Grk3-/- colony counts on the explanted spleen at day 8 were also increased in 
comparison to WT controls.  
While both Grk3-/- HSPC and whole bone marrow transplantation showed increased 
CFUs, the mechanism remains to be elucidated and will be the focus of future directions. It is 
possible the increased CFU numbers are due to enhanced hematopoietic cell proliferation, 
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homing abilities, or both. Therefore, as part of our short-term goals, we will first test whether 
GRK3 deficiency enhances HSPC proliferation in vivo through bromodeoxyuridine (BrdU) 
injections, which incorporates into the DNA during S-phase of the cell cycle and can be 
analyzed via flow cytometry. We will next test HSPC homing by utilizing allelic variants of 
CD45 in mice (CD45.1 and CD45.2) to distinguish between recipient (CD45.1) and donor 
(CD45.2) cells during analysis. We will test WT and Grk3-/- HSPC homing by transplanting 
equal numbers of Grk3-/- HSPCs or WT HSPCs (CD45.2) into B6.SJL-Ptprca Pepcb/BoyJ 
(CD45.1) recipient mice and harvesting the spleen at day 12 for flow cytometry analyses. 
We showed in Chapter 3 that Grk3-/- hematopoietic myeloid and lymphoid colony 
counts ex vivo increased with CXCR4 ligand stimulation (CXCL12), and Grk3-/- CFU-GM 
colony counts reduced to WT levels with CXCR4 antagonist treatment (AMD3100). Thus, 
our ex vivo CFU data suggest GRK3 regulates bone marrow hematopoietic growth of 
progenitor cells, at least in part, through CXCL12/CXCR4 stimulation. However, our recent 
finding that GRK3 regulates the S1P/S1PR pathway on BmMSCs (Chapter 2) suggests we 
must now consider and test whether S1P/S1PR may also be a player in our observed Grk3-/- 
HSPC phenotype since S1PRs are expressed on hematopoietic cells, including HSPCs, and 
are important for cell function [136]. Therefore, investigating GRK3 regulation of S1P/S1PR 
signaling on HSPCs will be the focus of future directions. 
Lastly, since it is our long-term goal to investigate the therapeutic potential of GRK3 
for immune reconstitution and engraftment, we plan to perform long-term transplantation 
studies using a similar experimental design as the homing assay with CD45.1/CD45.2 allelic 
variants that distinguish between recipient (CD45.1) and donor (CD45.2) cells during 
immune reconstitution analysis. CD45.1 recipients will be transplanted with either CD45.2 
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WT or Grk3-/- donor HSPCs. Experimental end-points will assess whether Grk3-/- HSPCs 
enhance cellular engraftment and immune reconstitution, in comparision to transplanted WT 
HSPCs, with the evaluation of mature leukocyte lineage repopulation (immune 
reconstitution) within the bone marrow, spleen, lymph nodes, and peripheral blood, and 
whether recipient host survival may be enhanced.  
In summary, our future directions will (1) test whether proliferation and/or homing is 
responsible for the increased number of Grk3-/- HSPCs in vivo, (2) investigate GRK3 
regulation of S1P/S1PR signaling in HSPCs, and (3) determine whether transplanted Grk3-/- 
HSPCs improve engraftment, hematopoiesis, and survival in HCT.  
 
Final Thoughts 
The intracellular signaling, regulatory mechanisms, and overall functionality of bone 
marrow niche cells are under active investigation and continually being defined within the 
field of hematopoiesis and stem cell research. The goal of this dissertation work is to provide 
further insight into the intracellular regulatory mechanisms and function of bone marrow 
niche cells in hopes to contribute to the overall understanding of the highly regulated, 
intricate cellular and molecular network within the bone marrow. Herein, we describe a 
newly elucidated pathway of regulation on two niche cells, BmMSCs and HSPCs. Our data 
suggest G protein-coupled receptor kinase 3 (GRK3) functions as a negative regulator of G 







APPENDIX 1: MOUSE MESENCHYMAL STEM CELL MARKER PANEL 
 
  
Appendix 1. Mouse mesenchymal stem cell marker panel. WT (top) and Grk3-/- 
(bottom) BmMSCs expression of positive markers CD106, CD73, CD44, CD29, Sca1 
and negative hematopoietic markers CD45 and CD11b (macrophage). Data plotted as 
percent (normalized to mode). 
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Appendix 2. GRK3-knockdown (GRK3-KD) BmMSCs have enhanced 
osteogenic differentiation in comparison to Non-target (NT) control BmMSCs. 
shRNA Non-target (NT) control and GRK3-knockdown (GRK3-KD) BmMSCs 
have comparable adipogenic differentiation (Oil Red O stain); however, GRK3-KD 
BmMSCs show enhanced osteogenic differentiation (Alizarin Red stain), similar to 
BmMSCs isolated from Grk3-/- mice. Images captured at 10X magnification using 
the Olympus 1X-81 microscope and MetaMorph software. 
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APPENDIX 3: CXCR4 mRNA EXPRESSION ON BmMSCS 
  
Appendix 3. WT and Grk3-/- BmMSCs express low levels 
of CXCR4 mRNA. Quantification of CXCR4 relative 
expression (2-ΔCT) normalized to housekeeping gene IDUA. 
Data represent mean ± SEM, n=5. 
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Appendix 4. BmMSC proliferation was not affected by CXCL12 stimulation or 
CXCR4 signaling inhibition with AMD3100. (A) Cellular proliferation was not 
enhanced in the presence of CXCL12, a CXCR4 agonist, at various concentrations, 
and (B) cellular proliferation was not reduced in the presence of AMD3100, a 
CXCR4 antagonist at various concentrations. Data represent mean ± SEM, n=3. 
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Appendix 5. WT and Grk3-/- BmMSCs have comparable sphingosine kinase 
activity. WT and Grk3-/- BmMSCs were treated with fluorescein-labeled sphingosine 
to assess the BmMSC ability to convert sphingosine to active ligand sphingosine-1-
phosphate (S1P) through sphingosine kinase (SphK) activity. WT and Grk3-/- 
BmMSC converted sphingosine into S1P (i.e.: SphK activity) at comparable levels. 
Data represent mean ± SEM, n=3. 
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Appendix 6. WT and Grk3-/- BmMSCs express S1PR1. (A) Immunoblot detection of 
S1PR1 from both WT and Grk3-/- BmMSC lysates, and (B) flow cytometry detection of 
surface S1PR1 (PE-conjugated) on Sca1+ (APC-conjugated) WT and Grk3-/- BmMSCs. 
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APPENDIX 7: BmMSC EXPRESSION OF S1PR3 
 
  
Appendix 7. WT and Grk3-/- BmMSCs express S1PR3. (A) Immunoblot detection of 
S1PR3 from both WT and Grk3-/- BmMSC lysates, and (B) flow cytometry detection of 




APPENDIX 8: DMSO VEHICLE TOXICITY WITH 
COMPARABLE DOSING AS VPC23019 
  
Appendix 8. DMSO vehicle toxicity evident at comparable dosing as VPC23019. 
BmMSC proliferation determined by increased formazan dye production from viable 
cells over time using CCK-8 proliferation assay. BmMSCs treated with (A) DMSO 





APPENDIX 9: BONE MARROW STEM AND PROGENITOR FLOW ANALYSES 
 
 
Appendix 9. WT and Grk3-/- hematopoietic stem and progenitor percent populations 
are comparable within the bone marrow. WT and Grk3-/- bone marrow analyzed by 
flow cytometry. (A) Lineage negative (Lin-) gating can be further subcategorized into 
MPPs (Sca1- c-Kit+), LSKs (Sca1+ c-Kit+), and Sca1lo c-Kitlo populations. (B) MPP gating 
can be further subcategorized into myeloid progenitors: common myleoid progenitors 
(CMP), granulocytic monocytic progenitors (GMP), and myeloid erythroid progenitors 
(MEP), (C) LSK gating can be further subcategroized into long-term HSCs (LT-HSC), 
short-term HSCs (ST-HSC), and common lymphoid progenitors (CLP). (D) Sca1lo c-Kitlo 















Appendix 10. Dose evaluation of CXCL12 for CFU assays. (A) CFU-GM CXCL12 
dose curve with peak response at 50 ηg/mL for Grk3-/- cultures. Data represent mean ± 
SEM, n=7 (control), n= 5 (10 ηg/mL), n=4 (50 ηg/mL), n=5 (100 ηg/mL). (B) CFU-
Pre-B CXCL12 dose curve with comparable response at 50 and 100 ηg/mL with a 





APPENDIX 11: AMD3100 INHIBITS COLONY PROLIFERATION 
 
Appendix 11. CXCR4 antagonist treatment (AMD3100) inhibits WT and Grk3-/- 
CFU-Pre-B colony proliferation. CFU-Pre-B cultures were treated with CXCR4 
ligand (CXCL12, 50 ηg/mL), CXCR4 antagonist (AMD3100, 1,000 ηg/mL), or both. 








Appendix 12. Grk3-/- LSK HSPCs do not more readily differentiate into myeloid 
(granulocytic and monocytic-GM) progenitors ex vivo. Assay optimization utilizing 
(A) 10 LSK HSPCs/well or (B) 25 LSK HSPCs/well for CFU-GM assay. Data represent 
mean ± SEM, n=3. 
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Appendix 13. Sphingosine kinase inhibitor (SKI)-treatment 
does not reduce BmMSC CXCL12 levels at early timepoints. 
Quantification of CXCL12 protein concentration from supernatant 
of untreated BmMSCs and treated BmMSCs with 5 µM SKI or 
vehicle (DMSO) at early timepoints (A) day 1 and day 2, and later 
timepoints (B) day 3 and day 4. Lower limit of detection at 46.9 
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